

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 831 856 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
07.08.2002 Bulletin 2002/32

(21) Application number: **96916821.0**

(22) Date of filing: **31.05.1996**

(51) Int Cl.7: **A61K 31/718, A61P 41/00**

(86) International application number:
PCT/US96/08098

(87) International publication number:
WO 96/40168 (19.12.1996 Gazette 1996/55)

(54) USE OF HYDROXYETHYL STARCH TO PREVENT POST SURGICAL ADHESION AND AS AN INTRACAVITY CARRIER DEVICE

VERWENDUNG VON HYDROXYETHYLSTÄRKE ZUR VERHINDERUNG POSTOPERATIVER
ADHÄSION UND ALS TRÄGER FÜR INNENHOHLRÄUME

UTILISATION D'AMIDON HYDROXYETHYLE POUR PREVENIR LES ADHERENCES
POST-CHIRURGICALES ET COMME DISPOSITIF DE SUPPORT ENDOCAVITAIRE

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

(30) Priority: **07.06.1995 US 482235**

(43) Date of publication of application:
01.04.1998 Bulletin 1998/14

(73) Proprietor: **UNIVERSITY OF SOUTHERN
CALIFORNIA**
Los Angeles, CA 90089 (US)

(72) Inventor: **DIZEREGA, Gere, Stodder**
Pasadena, CA 91105 (US)

(74) Representative: **Webber, Philip Michael**
Frank B. Dehn & Co.,
179 Queen Victoria Street
London EC4V 4EL (GB)

(56) References cited:
EP-A- 0 234 897 EP-A- 0 602 585

- **DATABASE WPI Week 9403 Derwent Publications Ltd., London, GB; AN 94-022820 XP002018924 & JP,A,05 331 053 (KIBUN FOOD ET AL.), 14 December 1993**
- **TRANSFUSION, vol. 25, no. 3, 1985, pages 230-230-234, XP000609632 R.G. STRAUSS ET AL.: "Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation, and fibrinolysis."**
- **J. LAB. CLIN. MED., vol. 108, no. 6, 1986, pages 556-561, XP000609619 M.E. CARR JR.: "Effect of hydroxyethyl starch on the structure of thrombin- and reptilase-induced fibrin gels." cited in the application**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 831 856 B1

Description**FIELD OF THE INVENTION**

5 [0001] The present invention relates to the use of hydroxyethyl starch in the preparation of a medicament for use as an absorbable mechanical barrier for minimizing or preventing postoperative adhesion formation between tissue, e.g., organ, surfaces in body cavities and for use as an intracavity carrier device for delivering pharmaceutical agents.

BACKGROUND OF THE INVENTION

10 [0002] Adhesion formation, in particular following peritoneal surgery, is a major source of postoperative morbidity and mortality. Appendectomy and gynecologic surgery are the most frequent surgical procedures implicated in clinically significant adhesion formation. The most serious complication of intraperitoneal adhesions is intestinal obstruction; in addition, adhesions are associated with chronic or recurrent pelvic pain and infertility in females.

15 [0003] The pathogenesis of adhesion formation is complex and not entirely understood. The first step is believed to involve excess fibrin deposition to form a scaffold. Organization of the fibrin scaffold by cellular elements, including fibroblasts and mesothelial cells, then follows.

[0004] Various approaches for the prevention of adhesion formation have been actively explored [diZerega, G.S. & Rodgers, K.E., "Prevention of Postoperative Adhesions," in "The Peritoneum," diZerega, G.S. & Rodgers, K.E., eds., Springer-Verlag, New York, pp. 307-369 (1992)]. In general, the treatments fall into three categories: prevention of fibrin deposition in the peritoneal exudate, reduction of local tissue inflammation; and removal of fibrin deposits.

[0005] Therapeutic attempts to prevent fibrin deposition include peritoneal lavages to dilute or wash away fibrinous exudate, surgical techniques to minimize tissue ischemia and introduction of barriers to limit apposition of healing serosal surfaces. Although the use of agents affecting coagulation of the fibrinous fluid has also been proposed, results obtained to date suggest that the use of procoagulants in areas of substantial bleeding may actually promote adhesion formation [Elkins, T.E., "Can a Pro-Coagulant Substance Prevent Adhesions?" in "Treatment of Post-Surgical Adhesions," diZerega, G.S. et al., eds., Wiley-Liss, New York, pp. 103-112 (1990)].

[0006] Physical barriers have been used in attempts to prevent adhesion formation by limiting tissue apposition during the critical period of peritoneal healing, thereby minimizing the development of fibrin matrix between tissue surfaces. Barrier agents which have been employed include both mechanical barriers and viscous solutions. Mixed results have been obtained using a barrier comprising a thin sheet of expanded poly-tetrafluoroethylene; in any event, such a membrane is less than ideal, as it must be sutured into place and is nonabsorbable. While an absorbable barrier (for example, a barrier made of oxidized regenerated cellulose) would be preferable, not all studies have demonstrated the efficacy of such barriers in preventing adhesions. Liquid barriers have also been considered for use in preventing adhesions; for example, chondroitin sulfate and carboxymethyl cellulose have both shown some promise in animal models. In addition, solution of dextran 70 (molecular weight = 70,000) has been the subject of a number of clinical studies. Not all clinical evaluations of 32% dextran 70 have found a therapeutic effect, however, and the clinical use of the solution is also associated with clinically important side effects.

[0007] Anti-inflammatory drugs have been evaluated for their effects on postoperative adhesion formation, as they may limit the release of fibrinous exudate in response to inflammation at the surgical site. Two general classes of these drugs were tested: corticosteroids and nonsteroidal anti-inflammatory drugs. The results of corticosteroid use in animal studies have generally not been encouraging, and clinical use of corticosteroids is limited by their other pharmacologic properties. While experimental evaluations of nonsteroidal anti-inflammatory drugs in postoperative adhesion formation show promise [Rodgers, K.E., "Nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of Postsurgical adhesion," in "Treatment of Post-Surgical Adhesions," diZerega, G.S. et al., eds., Wiley-Liss, New York, pp. 119-129 (1990)], clinical evaluation of these drugs for adhesion prevention is needed.

[0008] The third approach explored to date involves the removal of fibrin deposits. Although proteolytic enzymes (e.g., pepsin, trypsin and papain) should theoretically augment the local fibrinolytic system and limit adhesion formation, these enzymes are rapidly neutralized by peritoneal exudates rendering them virtually useless for adhesion prophylaxis. While various fibrinolytics (for example, fibrinolysin, streptokinase and urokinase) have been advocated, a potential complication to the clinical use of these enzymes in postoperative therapy is excessive bleeding resulting from their administration. Topical application of a recombinant tissue plasminogen activator (rt-PA) has been shown to reduce adhesion formation in a variety of animal models; further research is necessary to develop suitable delivery systems to provide this drug to the surgical site and identify the postoperative time when adhesion prevention is feasible.

55 [0009] To date, no single therapeutic approach has proven universally effective in preventing formation of postoperative intraperitoneal adhesions. Therefore, there is a need for compositions and methods which may be used safely and effectively to reduce or prevent postoperative adhesion formation in a variety of different contexts.

OBJECTS OF THE INVENTION

[0010] It is an object of the present invention to provide the use of hydroxyethyl starch (HES) in the preparation of a medicament for use as an absorbable mechanical barrier in a method for reducing or preventing adhesion formation at intracavitary injury sites following surgical procedures. HES can be effectively used alone or in combination with one or more anti-adhesion formation compounds.

[0011] It is another object of the invention to provide the use of HES in the preparation of a medicament for use as an intracavitary delivery device for delivering pharmaceutically active agents into body cavities.

[0012] These and other objects of the invention will be apparent in light of the detailed description below.

SUMMARY OF THE INVENTION

[0013] The present invention relates to HES and its utility in medical treatment. One embodiment of the invention relates to the use of HES in the preparation of a medicament wherein HES is employed as an absorbable mechanical barrier for reducing or preventing post-surgical adhesion formation between tissue, e.g., organ, surfaces at the injury site in a body cavity during tissue repair. The absorbable mechanical barrier remains at a site of potential adhesion formation for a period of time sufficient to permit substantial tissue repair (e.g., re-epithelialization or mesothelial repair) at the injury site. If desired, the HES barrier may include one or more compounds which reduce adhesion formation for an enhancement of this effect. Representative compounds having anti-adhesion formation effects include quina-crine, dipyridamole and analogs thereof, ketotifen and analogs thereof, manoalide and analogs thereof, retinoids, la-zaroids, and an anti-inflammatory corticosteroid, betamethasone.

[0014] Another embodiment of the present invention relates to the use of HES in the preparation of a medicament wherein HES is used as an intracavity carrier device for delivering pharmaceutically active agents to tissue, e.g., organ, surfaces in intracavity spaces. The pharmaceutically active agents may be covalently or non-covalently bound to HES or may simply be dispersed within HES.

DETAILED DESCRIPTION OF THE INVENTION

[0015] The present invention is based on the discovery that hydroxyethyl starch (HES) is useful in treatment methods as an absorbable mechanical barrier for minimizing or preventing formation of post-surgical adhesions between tissue surfaces in a body cavity and as an intracavity carrier device for delivering pharmaceutically active agents. HES is an amylopectin wherein hydroxyethyl groups have been substituted on a molar basis of between about 0.1 and about 0.8 (that is, one hydroxyethyl group for every 10 glucopyranose units to 8 hydroxyethyl groups for every 10 glucopyranose units), with amylopectin monomers having molecular weights ranging between about 3×10^4 and about 4×10^6 , preferably ranging between about 2×10^5 and about 2.4×10^6 daltons. For a review of HES, see, e.g., Thompson, W.L. (1978) "Hydroxyethyl Starch," in "Blood Substitutes and Plasma Expanders," Alan R. Liss, Inc., New York, NY, pp. 283-292. One form of HES, hetastarch (HES-7-8:10) or Hespan, is used commercially as a plasma volume expander and erythrocyte sedimenting agent and is comprised of more than 90% amylopectin which is etherified to the extent that approximately 7-8 hydroxyl groups present in every 10 D-glucopyranose units of the polymer have been converted to $\text{CH}_3\text{CH}_2\text{OH}$ groups. See "1993 Physicians' Desk Reference," pp. 967-68. In the Examples that follow, two forms of HES were evaluated: one form has one $\text{CH}_3\text{CH}_2\text{OH}$ group per 10 glucopyranose units (HES-1:10) and HES-7-8:10. Prior to the present invention, utility of HES as an absorbable mechanical barrier for adhesion formation prevention purposes and as an intracavity carrier device for delivery of pharmaceutically active agents was unknown.

[0016] One embodiment of the invention relates to the use of HES, e.g., HES-1:10 and HES-7-8:10, in the preparation of a medicament for use as an absorbable mechanical barrier for use in minimizing or preventing adhesion formation between tissue surfaces (not cell-to-cell adhesion) in a body cavity, the most common cause of which is prior surgery. HES was found to be effective alone in preventing adhesion formation in the peritoneum following surgery. In addition, the present invention finds utility in other contexts, e.g., for cardiovascular, orthopedic, thoracic, ophthalmic, CNS and other uses, where prevention of the formation of adhesions is a significant concern. For the purposes of the following discussion, attention is directed primarily to description of compositions and methods useful in inhibiting peritoneal adhesion formation.

[0017] HES shares gross similarities with dextran with regards to structure and clinical applications. Dextran has been shown to be useful in many clinical and animal studies to reduce adhesion formation. Two possible mechanisms have been proposed for Dextran's anti-adhesion formation effects. One mechanism is based on hydroflotation whereby large amounts of ascites formation was observed following Dextran application due to the hyperosmolality of the material tested. See, for instance, diZerega et al (1994) "Use of Instillates to prevent intraperitoneal Adhesions. Crystalloid and Dextran," *Infertility and Reprod. Med. Clinics of North America*, Vol. 5, pp. 463-78; and Cohen et al. (1983) "Use of Intraperitoneal Solutions for Preventing pelvic adhesions in the Rat," *J. Reprod. Med.*, Vol. 28, pp. 649-653. The

other mechanism is based on alterations in coagulation parameters. *Ibid.* In the animal studies outlined below, however, HES did not cause the formation of a significant ascites as would be observed with dextran.

[0018] Dextran containing formulations have been shown to reduce adhesion formation only when they are hyperosmolar. *Ibid.* The hyperosmolar formulations lead to ascites formation by the process of equilibration by the movement of fluid into the peritoneal cavity. *Ibid.* The ascites produces a hydroflotation media to separate tissue by flotation during the process of peritoneal repair. The Examples below show that HES effectively reduces adhesion formation in hyposmolar formulations. Thus, the mechanisms of action in adhesion prevention are distinctly different between dextran and HES. In addition, the literature suggests that HES does not affect fibrinolysis and coagulation to the same extent as dextran.

[0019] The effect of HES on coagulation parameters may depend upon the degree of derivatization and the molecular weight. Pentastarch (smaller MW and less derivatization) does not seem to alter coagulation parameters. Strauss et al. (1988) "Pentastarch may cause fewer effects on coagulation than hetastarch," *Transfusion*, Vol. 28, pp. 257-60; London et al. (1989) "A randomized clinical trial of 10% pentastarch (low molecular weight hydroethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations," *J. Thorac. Cardiovasc. Surg.*, Vol. 97: 785-97; Samana, C. et al. (1991) "Absence of side effects of hydroxyethyl starch 200 in a porcine model of experimental arterial thrombosis," *Thrombosis Res.*, Vol. 62, pp. 591-8. Furthermore, wash solutions containing HES did not prevent adhesion formation in animal model studies as discussed in JP-A-05331 053. Nor was any anti-adhesion effect noted in intraperitoneal dialysis solutions containing HES as an osmotically effective substance used as a glucose replacement as discussed in EP-A-0602585.

[0020] HES is seemingly cleared by macrophages therefore, there was a theoretical concern for decreased macrophage function. However, further studies have not supported this. No effect was shown on several WBC functions (phagocytosis, chemotaxis, cytokine release and release of inflammatory mediators). Eastlund, D. (1992) "Monocyte chemotaxis and chemotactic cytokine release after exposure to hydroxyethyl starch," *Transfusion*, Vol. 32, pp. 855-60; Strauss et al. (1986) "Ingestion of hydroxyethyl starch by human leukocytes," *Transfusion*, Vol. 26, pp. 88-90; Hain, H. et al. (1988) "Prostaglandin E₂, thromboxane B₂, and leukotriene B₄ release from peritoneal macrophages by different osmotic agents in nonuremic guinea pigs," *Trans. Am. Soc. Artif. Intern. Organs*, Vol. XXXIV, pp. 429-32.

[0021] The observed actions of HES is not in and of itself sufficient to enable one to predict whether it would have any utility in reduction of adhesion formation. For instance, HES shortened the lag time for thrombin-induced clotting time and augmented the lateral association of fibrin fibrils. However, HES also accelerates fibrinolysis, prolongs APTT time and decreases the production and procoagulant activity of Factor VIII. Therefore, the effects of HES on hemostatic parameters is mixed and it is difficult to predict one way or the other what effect, if any, HES would have with respect to adhesion formation. Carr, ME. (1986) "Effect of hydroethyl starch on the structure of thrombin- and reptilase-induced fibrin gels," *J. Lab. Clin. Med.*, Vol. 108, pp. 566-61; Kuitunen, A. et al. (1993) "Hydroethyl starch as a prime for cardiopulmonary bypass: Effects of two different solutions on haemostasis," *Acta Anaesthesiologica Scandinavica*, Vol. 37, pp. 652-8; Collins, R. et al. (1994) "The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation: an in vitro study," *Intensive Care Med.*, Vol. 20, pp. 37-41; Folk, JL et al. (1988) "Effects of hetastarch and albumin on coagulation in patients with septic shock," *J. Clin. Pharmacol.*, Vol. 28, pp. 412-5.

[0022] HES employed in the invention are amylopectins wherein hydroxyethyl groups have been substituted on a molar ratio ranging between about 0.1 and about 0.8 of a hydroxyethyl group per glucopyranose unit. The amylopectin monomers may have molecular weights ranging between about 3×10^4 and about 4×10^6 daltons, preferably ranging between about 2×10^5 and about 2.4×10^6 daltons. Preferred HES in practicing this invention are HES-1:10, HES-7-8:10 and HES-5:10 (commonly referred to as pentastarch). HES may be purchased from a variety of commercial sources including Sigma Chemical Company (St. Louis, MO, USA).

[0023] If desired, aggregated or crosslinked forms of HES may be used in the HES formulations of the present invention. Methods for inducing interactions between HES monomers are known in the art and include heating or irradiation. See, for example, Concettoni et al. (1992) "Thermic and UV instability of hetastarch," *Pharmacological Res.*, Vol. 25, pp. 87-88; and Concettoni et al. (1990) "Energy of Activation of hetastarch in a limited range of thermal exposition," *Acta Physiologica Hungaria*, Vol. 75 (Supp.), pp 59-60.

[0024] HES formulations may be prepared by dissolving a predetermined amount in water at temperatures ranging between about 25°C and about 100°C. It has been observed that HES-7-8:10 readily dissolves in water at room temperature while HES-1:10 requires higher temperatures, e.g., 100°C, to dissolve.

[0025] If desired, the HES stock solution is centrifuged to remove particulate matter and sterilized by autoclaving, by sterile filtration, or any suitable method. Upon cooling to room temperature, the sterile stock solution is diluted in appropriate volumes of a sterile physiologically acceptable vehicle to produce an HES formulation.

[0026] In general, the concentration of HES which can be administered would be limited by efficacy at the lower end and solubility or toxicity of the material at the upper end. In practice, the concentration of HES formulations generally range between about 0.1% and about 60% (w/v), preferably ranging between about 5.4% and about 34.3% (w/v), of HES in an aqueous vehicle. At the aforementioned concentration ranges, the HES formulations are hypotonic so as

to avoid hydroflotation and its resulting adverse physiological effects. However, any osmolarity can be provided, for instance, the compositions of the invention can be formulated so as to be isotonic or hypertonic to body tissues in a body cavity. Osmolarity can be adjusted by varying the amounts of HES used or using physiologically acceptable osmotically active substances.

[0027] HES formulations may be stored at a temperature generally ranging between about -20°C and about 30°C, preferably ranging between about 4°C and about 25°C, prior to use. An enhanced anti-adhesion formation effect was observed following storage of certain HES formulations, e.g., 13.5% HES-1:10, at 4°C prior to administration. Without being bound by any theory of operation of the invention, it is believed that low temperature storage had increased the viscosity of the HES composition.

[0028] Nonlimiting examples of physiologically acceptable vehicles include water, saline or aqueous buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and the like, such as sodium phosphate, citrate, borate, acetate, bicarbonate, carbonate and tromethamine (TRIS). The physiologically acceptable vehicles should not cause or aggravate irritation or inflammation on contact with the targeted site for application. Preferred vehicles for use in this invention include saline, phosphate buffered saline (PBS), citrate buffer, and Ringers lactate solution.

[0029] In practicing the present invention, it is preferred that HES compositions be further supplemented with anti-adhesion formation compounds for enhanced effect. Representative anti-adhesion formation compounds include the ones described, for instance, in U.S. Patent application Ser. No. 08/341,651 (US 5,614,515), filed November 17, 1994 for lazaroids; U.S. patent application Ser. No. 08/253,438 (US 5,478,837), filed June 7, 1994, for quinacrine; U.S. patent application Ser. No. 08/373,399 (US 5,534,261), filed January 16, 1995 for retinoids; U.S. Patent application Ser. No. 08/253,437 (US 5,498,613), filed June 7, 1994 for dipyrindamole; U.S. Patent application Ser. No. 08/473,183, filed concurrently with the present application, for METHOD FOR REDUCING OR PREVENTING POST-SURGICAL ADHESION FORMATION USING 5-LIPOXYGENASE INHIBITORS by Kathleen Elizabeth Rodgers and Gere Stodder diZerega (University of Southern California, assignee); U.S. Patent application Ser. No. 08/479,128, filed concurrently with the present application, for METHOD FOR REDUCING OR PREVENTING POST-SURGICAL ADHESION FORMATION USING MANOALIDE AND ANALOGUES THEREOF by Kathleen Elizabeth Rodgers and Gere Stodder diZerega (University of Southern California, assignee); and U.S. Patent application Ser. No. 08/472,299 (US 5,891,460), filed concurrently with the present application, for METHOD FOR REDUCING OR PREVENTING POST-SURGICAL ADHESION FORMATION USING KETOTIFEN AND ANALOGS by Kathleen Elizabeth Rodgers and Gere Stodder diZerega (University of Southern California, assignee). Other representative anti-adhesion formation agents include NSAIDS such as Tolmetin and Ibuprofen; and anti-inflammatory corticosteroids such as Betamethasone and Dexamethasone. Betamethasone is a particularly potent anti-adhesion formation agent and its use in conjunction with the HES composition of the present invention is exemplified in the Examples below.

[0030] If desired, the HES formulations of the present invention may also contain preservatives, cosolvents, suspending agents, viscosity enhancing agents, ionic strength and osmolality adjusters and other excipients in addition to buffering agents. Suitable water soluble preservatives which may be employed in the drug delivery vehicle include sodium bisulfite, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric borate, parabens, benzyl alcohol, phenylethanol or antioxidants such as Vitamin E and tocopherol and chelators such as EDTA and EGTA. These agents may be present, generally, in amounts of about 0.001% to about 5% by weight and, preferably, in the amount of about 0.01 to about 2% by weight.

[0031] Pursuant to the method of the present invention, HES is maintained in an effective concentration at the site of potential adhesion formation for a period of time sufficient to permit substantial reepithelialization. HES is typically administered over the intraoperative interval, which for purposes of the present invention may include the time at the beginning of surgery through the surgery itself up to some time just prior to completion of surgery. In practicing the invention, the HES composition is preferably administered in a single dose (for example, prior to skin closure after surgery). If desired, the HES composition may be administered repeatedly during surgery.

[0032] In general, the amount of HES formulation which may administered at the injury site ranges between about 0.2 and about 100 ml/Kg body weight, preferably ranging between about 2 and about 10 ml/Kg body weight.

[0033] In another embodiment of the invention, HES formulations may be used as an intracavity carrier device to deliver a pharmaceutically active agent to a targeted body cavity such as the rectum, urethra, nasal cavity, vagina, auditory meatus, oral cavity, buccal pouch, peritoneum, pleura, articular space, central nervous system (e.g., intradural spaces) tendinous space, paraspinal space. As would be readily apparent to one working in the field, the pharmaceutical agent may be covalently or non-covalently (e.g., ionically) bound to such a barrier, or it may simply be dispersed therein.

[0034] When used as an intracavity carrier device, the HES formulations contain an effective amount of a pharmaceutically active agent such as a drug, generally ranging from between about 0.001% to about 10% by weight of the agent, preferably ranging between about 0.01% and about 5%. Co-solvents such as DMSO or ethanol may be used to enhance drug solubility of water insoluble pharmaceutically active agents. Insoluble drugs can often be suspended with the aid of suitable suspending or viscosity-enhancing agents.

[0035] Suitable, but non-limiting classes of pharmaceutically active agents which can be administered to a body cavity by the intracavity carrier device of the present invention include antibacterial substances such as β -lactam antibiotics like cefoxitin, penicillin, clindamycin, metronidazole, ampicillin, cephalosporin, n-formamidoyl thienamycin and other thienamycin derivatives, tetracyclines, chloramphenicol, neomycin, gramicidin, bacitracin, sulfonamides; aminoglycoside antibiotics such as gentamycin, kanamycin, amikacin, sisomicin and tobramycin; nalidixic acids and analogs such as norfloxacin and the antimicrobial combination of fluoro-alanine/pentizidone; nitrofurazones, and the like; antihistaminics and decongestants such as pyrilamine, chlorpheniramine, tetrahydrozoline, antazoline, and the like; anti-inflammatories such as cortisone, hydrocortisone, betamethasone, dexamethasone, fluocortisone, prednisolone, triamcinolone corticosteroids, indomethacin, sulindac, ibuprofen, tolmetin and flubiprofen, its salts and its corresponding sulfide, and the like. Also included are antiviral compounds such as acyclovir; fibrinolytic enzymes such as tissue plasminogen activator, streptokinase, and urokinase; cytokines such as tumor necrosis factor, interleukin-1, and interferon; and growth factors such as epidermal growth factor, and transforming growth factor as classes of compounds to deliver via this vehicle. EP-A-0234897, for instance, describes administration of a glucocorticoid, e.g., dexamethasone, for adhesion prevention.

[0036] For treatment of vaginal and urethral conditions requiring antifungal, amoebocidal, trichomonacidal agents or antiprotozoals, the following agents can be used: polyoxyethylene nonylphenol, alkylaryl sulfonate, oxyquinolin sulfate, miconazole nitrate, sulfanilamide, candicidin, sulfisoxazole, mystatin, chlortrimazole, metronidazole and the like and antiprotozoals such as chloramphenicol, chloroquine, trimethoprim, sulfamethoxazole and the like, antineoplastics such as cisplatin and 5-fluorouracil.

[0037] The medicaments of the present invention may be applied to the targeted site by any suitable means. In general, intracavitary administration is dependent upon the body space, e.g. pouring into the peritoneal cavity and injection into the intra-articular space.

[0038] The invention may be better understood with reference to the accompanying examples, which are intended to be

Examples

[0039] Multiple studies were performed to confirm the efficacy of HES compositions alone or in combination with an anti-adhesion compound in the reduction of adhesion formation following peritoneal surgery. Two model systems were employed: the sidewall adhesion model and the uterine horn model. A clear correlation between results obtained using both of these models and utility in adhesion prevention has been demonstrated with INTERCEED(TC7), for which clear clinical efficacy has been shown and FDA approval for adhesion prevention in gynecological surgery has been obtained.

[0040] In the peritoneal sidewall model, rabbits were pre-anesthetized with 1.2 mg/kg acetylpromazine and anesthetized with a mixture of 55 mg/kg ketamine hydrochloride and 5 mg/kg xylazine intramuscularly. Following preparation for sterile surgery, a midline laparotomy was performed. A 3 x 5-cm area of peritoneum and transversus abdominis muscle was removed on the right lateral abdominal wall. The cecum was exteriorized, and digital pressure was exerted to create subserosal hemorrhages over all cecal surfaces. The cecum was then returned to its normal anatomic position. The compound to be tested was placed in an Alzet miniosmotic pump (Alza Corporation, Palo Alto, CA, USA) to allow continuous release of the molecule through the postsurgical interval. The Alzet miniosmotic pump was placed in the subcutaneous space and a delivery tube connected the pump with the site of injury at sidewall. Vehicle was placed in the pump of control rabbits. The abdominal wall and skin were closed in a standardized manner.

[0041] After 7 days, the rabbits were sacrificed and the percentage of the area of the sidewall injury that is involved in adhesions was determined. In addition, the tenacity of the adhesion formed was scored using a system as follows:

0 = No adhesions

1 = mild, easily dissectable adhesions

2 = moderate adhesions; non-dissectable, does not tear organ

3 = dense adhesions; non-dissectable, tears when removed

A reduction in the area or the tenacity of the adhesions would be considered beneficial.

[0042] In additional experiments, a rabbit uterine horn model was employed. This model has been previously shown to cause severe adhesions in rabbits after surgery [Nishimura, K. et al., "The Use of Ibuprofen for the Prevention of Postoperative Adhesions in Rabbits," *Am. J. Med.*, Vol. 77, pp. 102-106 (1984)]. The rabbits were anesthetized (130 mg/kg ketamine and 20 mg/kg acetylpromazine im) and prepared for sterile surgery. A midline laparotomy was performed and both uterine horns were surgically traumatized by abrading the serosal surface with gauze until punctate

bleeding developed. Ischemia of both uterine horns was induced by removal of the collateral blood supply. In some studies, the materials were delivered to the site of injury via Alzet miniosmotic pumps and tubes as described above. In other studies, a portion of the test compositions were applied at the site of injury at the end of surgery and any remaining material was applied through the incision site prior to closing. Controls include surgical and vehicle controls.

The abdominal wall and skin were closed in a standardized manner.

[0043] After 7 days, the rabbits were sacrificed and the percentage of the area of the uterine horn injury that is involved in adhesions was determined. An initial score to represent the overall extent of adhesions is given (0 to 4+). The percentage of a surface of the horn involved in adhesions to various organs are given in the tables below the overall adhesion score.

[0044] In the model systems employed in the examples reported herein, compositions comprising HES were shown to reduce the incidence of peritoneal adhesions. In these Examples, rabbits received various volumes of test composition. The HES concentration of the test compositions ranged from between about 5.4% and about 40%. Other test compositions included anti-adhesion drug compounds such as quinacrine, lazaroide and betamethasone.

Example 1: Preparation of HES Compositions

[0045] HES-1:10 (6.15 grams, Cat. No. H 6382 Sigma Corporation, St. Louis, MO, USA) was resuspended in water (100 ml) using a magnetic stirrer and heated to 85°C to dissolve the HES-1:10. The solutions were then boiled for approximately 1 minute and allowed to cool. The material was centrifuged for 10 minutes at 1000 x g to remove large pieces of undissolved particulate matter, placed in an autoclave and heated to sterilize. After autoclaving, the preparation was diluted with either vehicle or drug (9 parts HES-1:10 with 1 part vehicle depending upon the test group). Thereafter, the materials were placed in a syringe and stored at room temperature or at 4 C. Storage at room temperature did not appear alter the viscosity of the HES-1:10 solution to the same extent. However, storage at 4 C for 3 to 5 weeks resulted in an increase in viscosity to a point of solidification in the higher percentage HES-1:10 solutions.

[0046] With respect to HES-7-8:10, a predetermined amount of HES-7-8:10 was diluted in distilled water and mixed at a dilution of 9 parts HES to 1 part 10x drug or vehicle. The percentages were made on a wt/vol basis. After mixing, the formulations were sterilized by filtration or autoclaving. The materials and procedures for preparing HES formulations are as follows:

Diluents: a) Saline - 0.85% NaCl in deionized or distilled water and autoclaved to sterilize (termed saline in table below); b) PBS - 0.01 M sodium phosphate, 0.1 M NaCl, pH 7.4, autoclave to sterilize; c) Citrate Buffer - 0.02 M citric acid, 0.0032 M sodium citrate, 0.077 M NaCl, pH 3.5, sterile filter (termed citrate in table below).

Drugs: These were dissolved in an appropriate buffer or salt solution at a concentration 10 fold the final concentration. The 10x drug solutions were diluted 1:10 with the corresponding sterile HES-1:10 or HES-7-8:10 solution to yield a 1x drug concentration and a 9:10 HES-1:10 concentration. For example, a stock 15% HES-1:10 solution diluted 9:10 with either saline or 10x drug in saline will give a final 1x drug level in 13.5% HES-1:10.

[0047] Osmolality measures of several of the test formulations used in the Examples are given below:

HES	% (w/v)	Buffer	mmol/kg
HES-1:10	5.4%	10% Saline	42
	8.1%	10% Saline	36
	10.8%	10% Saline	46
	13.5%	10% Saline	47
	5.4%	10% Citrate	37
	8.1%	10% Citrate	38
	10.8%	10% Citrate	48
	13.5%	10% Citrate	42
HES-7-8:10	9%	Water	47
	12%	Water	52
	15%	Water	62
	18%	Water	102

Example 2: Evaluation of HES-1:10/Quinacrine compositions

[0048] In this Example, 10.8% (w/v) or 13.5% (w/v) HES-1:10 compositions alone or in combination with quinacrine (0.5 mg/ml) were evaluated in the rabbit uterine horn model for adhesion prevention. Quinacrine, an antimalarial drug, was found to have a post-surgical anti-adhesion formation effect as disclosed in co-pending U.S. patent application No.08/253,438(US 5,478,837), filed June 7, 1994. The composition was administered in a volume of 5 ml at the end of surgery and the animals were sacrificed at day 7. The control was surgery only. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 1 and 2.

HES-1:10 alone and in combination with quinacrine was found to be efficacious in reducing adhesions in the rabbit double uterine horn model.

TABLE 1

HES-1:10 + Quinacrine	
Treatment	Overall Score
Surgical Control	3+ 2.5+ 2.5+ 3+ 3+
13.5% RT HES-1:10	2.5+ 2+ 2+ 2+ Died D3 P/O
13.5% RT HES-1:10 + Quinacrine	0.5+ Infection 1.5+ 1.5+ 1+
13.5% 4C HES-1:10	2+ 1+ 1.5+ 1.5+ 1.5+
13.5% 4C HES-1:10 + Quinacrine	1.5+ 1+ 1.5+ 1.5+ 2+
10.8% RT HES-1:10	2+ 2+ 1+ 2.5+ 1+

EP 0 831 856 B1

TABLE 1 (continued)

HES-1:10 + Quinacrine	
Treatment	Overall Score
10.8% RT HES-1:10 + quinacrine	2+ 1.5+ 1.5+ 1+ 1.5+
10.8% 4C HES-1:10	1.5+ 2.5+ 1+ Died D1 P/O 2+
10.8% 4C HES-1:10 + quinacrine	1.5+ 1+ 2+ 1.5+ 1.5+
0.5 mg/ml Quinacrine	1.5+ 1.5+ 1+ 1+ 1.5+

TABLE 2

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	50	50	40	0	50	50	50	0
	30	50	30	0	30	50	40	0
	30	30	40	20	30	30	30	20
	30	40	50	30	30	40	50	30
	40	50	40	40	40	50	20	40+
Mean	36	44	40	18	36	44	40	18
13.5% RT HES-1:10	30	30	20	20	30	30	30	20
	0	20	20	20	0	20	20	20
	30	10	30	10	30	10	20	10*
	20	10	30	20	20	10	20	20
	DIED D3 P/O							
Mean	20	17.5	25	17.5	20	17.5	22.5	17.5
13.5% RT HES-1:10 + Quinacrine	0	0	10	0	0	0	20	0
	INFECTION							
	10	0	20	20	10	0	20	20

EP 0 831 856 B1

TABLE 2 (continued)

% Organ Involvement in Uterine Horn Adhesion								
	INFECTION							
	0	10	30	10	0	10	0	10
	0	0	20	10	0	0	10	10*
Mean	2.5	2.5	20	10	2.5	2.5	12.5	10
13.5% 4C HES-1:10	20	0	30	10	40	0	0	10
	0	20	10	0	0	20	20	0
	0	10	20	10	0	10	10	10
	0	10	20	20	0	10	30	20
	10	0	10	10	10	0	10	10
Mean	6	8	18	10	10	8	14	10
13.5% 4C HES-1:10 + Quinacrine	10	10	10	0	10	10	20	0
	0	20	20	0	0	20	20	0
	0	10	20	30	0	10	20	30*
	0	0	40	10	0	0	30	10*
	20	30	20	20	20	30	20	20*
Mean	6	14	22	12	6	14	22	12
10.8% RT HES-1:10	0	50	30	0	0	50	30	0
	0	30	20	10	0	30	30	10
	10	20	20	0	0	20	0	0
	10	20	30	40	10	20	40	40
	0	10	10	10	0	10	10	10
Mean	4	26	20	12	2	26	22	12
10.8% RT HES-1:10+ Quinacrine	30	10	20	0	30	10	30	0
	20	10	10	0	20	10	0	0
	0	10	30	30	0	10	30	30
	0	10	0	0	0	10	10	0
	0	20	20	10	0	20	20	10*
Mean	10	12	16	8	10	12	18	8
10.8% 4C HES-1:10	0	20	20	20	0	20	20	20
	20	10	10	10	20	10	10	10+, *
	0	0	20	10	0	0	20	10
	DIED D1 P/O							
Mean	0	40	30	20	0	40	20	20
	5	17.5	20	15	5	17.5	17.5	15
10.8% 4C HES-1:10 + Quinacrine	10	0	20	10	10	0	30	10
	10	0	10	0	0	0	20	0
	20	10	20	10	20	10	0	10*
	10	0	30	20	10	0	0	20*
	0	20	20	20	0	20	10	20

* Material present on horns

+ Horns with incision

RT HES-1:10 stored at room temperature, any viscosity due to concentration of HES-1:10 (this terminology was used throughout the patent)

4C HES-1:10 stored in a refrigerator, this increased viscosity (this terminology was used throughout the patent)

EP 0 831 856 B1

TABLE 2 (continued)

% Organ Involvement in Uterine Horn Adhesion								
	DIED D1 P/O							
Mean	10	6	20	12	8	6	12	12
Quinacrine	10	10	30	20	10	10	30	20
	0	0	30	10	0	0	30	10
	0	0	20	10	0	0	20	10
	0	10	30	0	0	0	20	0
	0	0	30	10	0	0	30	10
Mean	2	4	28	10	2	2	26	10

[0049] Statistical analysis was performed on the overall score of the nonparametric data taken from Table 1. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below. Comparison of the rank order of 13.5% RT HES-1:10 with 13.5% RT HES-1:10 + quinacrine gives a p value of 0.000.

Treatment	Rank order	p value
Control	44.4 ± 2.0	
13.5% RT HES-1:10	36.4 ± 3.3	0.001
13.5% RT HES-1:10 + quinacrine	12.1 ± 8.6	0.000
13.5% 4C HES-1:10	20.5 ± 8.9	0.000
13.5% 4C HES-1:10 + quinacrine	20.5 ± 8.9	0.000
10.8% RT HES-1:10	24.8 ± 15.2	0.021
10.8% RT HES-1:10 + quinacrine	20.5 ± 8.9	0.000
10.8% 4C HES-1:10	25.9 ± 13.6	0.017
10.8% 4C HES-1:10 + quinacrine	20.5 ± 8.9	0.000
Quinacrine	14.9 ± 3.1	0.000

Example 3: Evaluation of HES-1:10/Quinacrine compositions

[0050] This Example is similar to Example 2, except that 5.4% (w/v) and 8.1% (w/v) HES-1:10 compositions alone or in combination with (0.5 mg/ml) quinacrine were evaluated for adhesion prevention. The composition was administered at the end of surgery in a volume of 5 ml and the animals were sacrificed at day 7. One control was treated with saline vehicle (termed saline on the table) and the other had surgery only (surgical control). The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 3 and 4. HES-1:10 alone and in combination with quinacrine was efficacious at the reduction of adhesions in the rabbit double uterine horn model.

TABLE 3

HES-1:10 + Quinacrine	
Treatment	Overall Score
Surgical Control	3+
	2.5+
	2.5+
	2.5+
	2.5+
8.1% RT HES-1:10	1.5+
	1+

TABLE 3 (continued)

HES-1:10 + Quinacrine	
Treatment	Overall Score
8.1% RT HES-1:10 + Quinacrine	0.5+
	1.5+
	1.5+
	2+
	1.5+
8.1% 4C HES-1:10	2+
	1.5+
	1+
	2.5+
	1.5+
8.1% 4C HES-1:10 + Quinacrine	1.5+
	0.5+
	1+
	1+
	1+
5.4% RT HES-1:10	2+
	1.5+
	2.5+
	2.5+
	1.5+
5.4% RT HES-1:10 + Quinacrine	1+
	Died
	1.5+
	1.5+
	1.5+
5.4% 4C HES-1:10	2+
	1.5+
	1.5+
	2+
	1.5+
5.4% 4C HES-1:10 + Quinacrine	1.5+
	2+
	1.5+
	1+
	1.5+
Saline	1.5+
	2+

EP 0 831 856 B1

TABLE 3 (continued)

HES-1:10 + Quinacrine	
Treatment	Overall Score
	2+
	2.5+
	1.5+

TABLE 4

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	0	100	30	30	0	100	30	30
	0	60	30	30	0	60	20	30
	0	50	40	30	0	50	30	30
	20	30	40	40	20	30	30	40
	30	20	20	20	30	20	30	20
Mean	10	52	32	30	10	52	28	30
8.1% RT HES-1:10	0	20	20	0	0	20	20	0
	0	10	20	0	0	10	10	0
	0	0	20	0	0	0	10	0*
	10	10	20	10	10	10	20	10+
	0	20	20	0	0	20	20	0
Mean	2	12	20	2	2	12	16	2
8.1% RT HES-1:10 + Quinacrine	20	30	20	0	20	30	10	0
	0	20	20	0	0	20	10	0
	10	10	30	10	10	10	20	10*
	0	0	20	10	0	0	20	10
	0	20	20	0	0	20	20	0
Mean	6	16	22	4	6	16	16	4
8.1% 4C HES-1:10	10	20	20	10	10	20	30	10
	10	10	20	10	10	10	0	10
	0	20	20	0	0	20	0	0
	30	30	20	20	30	30	20	20+
	20	0	10	10	20	0	10	10+
Mean	14	16	18	10	14	16	12	10
8.1 % 4C HES-1:10 + Quinacrine	0	10	10	10	0	10	10	10
	0	0	10	0	0	10	0	0
	0	0	10	10	0	0	10	10*
	0	0	10	10	0	0	30	10
	0	0	20	0	0	10	10	0
Mean	0	2	12	6	0	6	10	6
5.4 % RT HES-1:10	20	10	10	10	20	10	10	10

+ Material present on horns

* Small amount of ascites

TABLE 4 (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5.4% RT HES-1:10 + Quinacrine	0	10	10	10	0	10	20	10
	40	10	30	30	40	10	20	30
	30	10	20	20	30	10	20	20
	20	20	0	0	20	20	20	0
	22	12	14	14	22	12	18	14
	0	0	20	20	0	0	10	20
DIED								
Mean	10	10	10	10	10	10	10	10
	0	10	20	20	0	10	20	20
	10	0	10	20	10	0	20	20
	5	5	15	17.5	5	5	15	17.5
5.4% 4C HES-1:10	10	20	20	10	10	20	10	10
	10	10	20	0	10	10	10	0
	10	0	20	0	10	0	20	0
	20	0	20	30	20	0	20	30
Mean	10	20	20	0	10	20	20	0
	12	10	20	8	12	10	16	8
5.4% 4C HES-1:10 + Quinacrine	0	20	20	0	0	20	20	0
	10	10	20	0	0	10	20	0
	10	10	20	10	10	10	20	10
	0	0	10	10	0	0	10	10
Mean	20	0	20	20	20	0	20	20
	8	8	18	8	6	8	18	8
Saline	0	10	20	10	0	10	10	10
	20	30	20	20	20	30	20	20
	30	30	0	20	30	30	0	20
	10	30	20	40	10	30	20	40
Mean	10	0	20	10	10	0	10	10
	14	20	16	20	14	20	12	20

[0051] Statistical analysis was performed on the overall score of the nonparametric data taken from Table 3. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below. Comparison of the rank order of 8.1% 4C HES-1:10 with 8.1% 4C HES-1:10 + quinacrine gives a p value of 0.029 and comparison of 5.4% RT HES-1:10 with 5.4% RT HES-1:10 + quinacrine gives a p value of 0.020.

Treatment	Rank order	p value
Control	45.4 ± 1.8	
8.1% RT HES-1:10	14.6 ± 8.6	0.000
8.1% RT HES-1:10 + quinacrine	21.5 ± 13.0	0.004
8.1% 4C HES-1:10	26.1 ± 13.1	0.011
8.1% 4C HES-1:10 + quinacrine	8.8 ± 6.7	0.000
5.4% RT HES-1:10	33.6 ± 10.4	0.037

(continued)

Treatment	Rank order	p value
5.4% RT HES-1:10 + quinacrine	17.9 ± 6.3	0.000
5.4% 4C HES-1:10	27.3 ± 7.1	0.000
5.4% 4C HES-1:10 + quinacrine	21.5 ± 9.2	0.000
Saline	31.9 ± 9.0	0.011

Example 4: Evaluation of HES-1:10/Lazaroid Compositions

[0052] In this Example, compositions containing 13.5% (w/v), 10.8% (w/v), 8.1% (w/v) or 5.4% (w/v) HES-1:10 alone or in combination with a lazaroid (0.6 mg/ml, U-83836-E, available from the UpJohn Company, Kalamazoo, MI, USA) were evaluated in the rabbit uterine horn model for adhesion prevention. Lazaroids were found to have a post-surgical anti-adhesion formation effect as disclosed in co-pending U.S. patent application No. 08/341,651, filed November 17, 1994, which is incorporated herein in its entirety. The composition was administered in a volume of 5 ml at the end of surgery and the animals were sacrificed at day 7. The control was surgery only. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 5 and 6. HES-1:10 alone and in combination with lazaroid was found to be efficacious in reducing adhesions in the rabbit double uterine horn model.

TABLE 5

HES-1:10 + LAZAROID	
Treatment	Overall Adhesion Score
Surgical Control	2+
	2.5+
	2.5+
	2.5+
	2.5+
	3+
	2.5+
	2.5+
	3+
13.5% RT HES-1:10	1.5+
	1.5+
	1.5+
	2+
	1.5+
13.5% RT HES-1:10 + Lazaroid	2+
	1.5+
	1.5+
	1.5+
13.5% 4C HES-1:10	0.5+*
	1.5+
	1.5+

* These data are from the last day of surgery on the first half of the study. The formulations tested in the animals represented by these data were stored an additional 5 days prior to testing. With storage, an increase in viscosity was probably and this may account for the increase efficacy noted.

EP 0 831 856 B1

TABLE 5 (continued)

HES-1:10 + LAZAROID	
Treatment	Overall Adhesion Score
5 10	1.5+
	1.5+*
	1.5+
	2+
	1.5+
15	1.5+
	0.5+
	2.5+
	2.5+
	2+
20	1.5+*
	1.5+
	2+
	1.5+
	1+
25	1+*
	2+
	1.5+
	2+
	2+
30	1.5+*
	2+
	1+
	1+
	2+
35	2+
	1+
	1+
	2+
	2+
40	1+*
	2+
	2+
	3+
	1.5+
45	1.5+
	1+
	1.5+
	1.5+
	1+
50	2+
	2+
	3+
	1.5+
	1.5+
55	2+

* These data are from the last day of surgery on the first half of the study. The formulations tested in the animals represented by these data were stored an additional 5 days prior to testing. With storage, an increase in viscosity was probably and this may account for the increase efficacy noted.

EP 0 831 856 B1

TABLE 5 (continued)

HES-1:10 + LAZAROID	
Treatment	Overall Adhesion Score
5	2.5+
	2+
	2+
	1.5+
10	1+
	1.5+
	1+
	1+
15	1+
	2.5+
	1.5+
	1.5+
20	1+
	2+
	1.5+
	1.5+
25	1.5+
	1.5+
	2+
	1.5+
30	1.5+
	2+
	3.5+
	1.5+
35	1.5+
	1.5+
	1.5+
	1.5+
40	1.5+
	1.5+
	2+
	1.5+
45	1.5+
	1+
	1+
	2.5+
50	2+
	1.5+
	2+
	1+
	1.5+*

* These data are from the last day of surgery on the first half of the study. The formulations tested in the animals represented by these data were stored an additional 5 days prior to testing. With storage, an increase in viscosity was probably and this may account for the increase efficacy noted.

TABLE 6

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	20	10	20	20	20	10	10	20
	40	20	20	20	40	20	20	20
	20	20	20	30	20	20	20	30
	10	40	20	0	10	40	20	0+
	30	30	20	40	30	30	20	40+
	30	30	20	30	30	30	30	30+
	30	10	20	40	30	10	20	40
13.5% RT HES-1:10	30	30	40	20	30	30	40	20
	40	20	20	20	40	20	20	20+
	50	20	40	30	50	30	40	30
	Mean	30	23	24	30	23	24	25
13.5% RT HES-1:10 +Lazaroid	0	0	30	20	0	0	20	20
	10	20	20	0	10	20	10	0
	20	0	10	20	20	0	10	20
	20	10	20	0	20	10	20	0+
	20	10	20	0	20	10	10	0
Mean	14	8	20	8	14	8	14	8
13.5% 4C HES-1:10	30	0	10	30	30	0	30	30+
	20	20	20	0	20	20	10	0
	20	0	20	20	20	0	10	20
	10	0	10	10	10	0	20	10
	0	0	20	0	0	0	10	0
Mean	16	4	16	12	16	4	16	12
13.5% 4C HES-1:10 +Lazaroid	30	0	20	10	30	0	20	10
	0	20	10	10	0	20	10	10
	10	10	10	20	10	10	10	20
	20	20	10	0	20	20	10	0
	20	0	10	10	20	0	10	10
Mean	16	10	12	10	16	10	12	10
10.8% RT HES-1:10	20	0	20	0	20	10	10	0**
	20	10	20	10	20	10	10	10
	20	0	10	10	20	0	10	10
	30	0	20	0	30	0	20	0
	10	20	20	10	10	20	20	10
Mean	20	6	18	6	20	8	14	6
10.8% RT HES-1:10	0	0	10	0	0	0	0	0
	10	40	20	0	10	40	20	0
	40	20	20	0	40	20	10	0+

+ Organ with incision

** Material present

RT = HES-1:10 stored at room temperature, any viscosity due to concentration of HES-1:10.

4C = HES-1:10 stored in a refrigerator, this increases viscosity.

EP 0 831 856 B1

TABLE 6 (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Mean	10	30	20	0	10	30	20	0
	10	10	10	10	10	10	10	10
	14	20	16	2	14	20	12	2
	30	0	20	0	30	0	20	0**
	10	20	20	0	10	20	20	0**
10.8% RT HES-1:10 +Lazaroid	30	0	20	0	30	0	0	0
	20	0	10	0	20	0	10	0
	0	0	20	10	0	0	10	10**
	18	4	18	2	18	4	12	2
	20	30	30	20	20	30	40	20
10.8% 4C HES-1:10	10	0	20	10	10	0	20	10**
	0	40	10	10	0	40	10	10
	10	20	20	0	10	20	10	0+
	10	0	20	10	10	0	20	10
	10	18	20	10	10	18	20	10
Mean	20	10	20	20	20	10	20	20
	0	0	20	10	0	0	20	10**
	0	0	20	10	0	0	20	10+
	10	10	20	20	10	10	20	20
	0	10	10	0	0	10	10	0
10.8% 4C HES-1:10 +Lazaroid	6	6	18	12	6	6	18	12
	30	10	30	0	30	10	30	0
	40	0	10	20	40	0	10	20**
	30	0	30	50	30	0	20	50
	20	20	10	10	20	20	0	10**
Mean	0	20	10	20	0	20	10	20
	24	10	18	20	24	10	14	20
	10	0	0	20	0	0	0	0
	20	0	20	10	20	0	20	10**
	10	0	20	10	10	0	20	10**
8.1% RT HES-1:10	20	40	0	0	20	40	0	0
	20	0	0	0	20	0	10	0
	16	8	8	8	14	8	10	8
	20	0	20	20	20	0	20	20
	40	10	20	20	40	10	20	20
Mean	30	0	30	20	20	0	10	20**
	30	10	20	20	30	10	10	20+
	0	10	10	20	0	10	10	20
	24	6	22	20	24	6	14	20
	20	0	20	20	20	0	20	20
8.1% 4C HES-1:10	40	10	20	20	40	10	20	20
	30	0	30	20	20	0	10	20**
	30	10	20	20	30	10	10	20+
	0	10	10	20	0	10	10	20
	24	6	22	20	24	6	14	20

+ Organ with Incision

** Material present

RT = HES-1:10 stored at room temperature, any viscosity due to concentration of HES-1:10.

4C = HES-1:10 stored in a refrigerator, this increases viscosity.

EP 0 831 856 B1

TABLE 6 (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
8.1% 4C HES-1:10 +Lazaroid	0	0	10	10	0	0	20	10+
	30	0	10	10	30	0	10	10**
	0	10	10	0	0	10	10	0
	0	0	10	10	0	0	20	10**
	30	0	10	0	30	0	10	0**
Mean	12	2	10	6	12	2	14	6
5.4% RT HES-1:10	20	0	20	40	20	0	20	40**
	20	10	10	10	20	10	10	10
	20	0	20	10	20	0	20	10+
	0	0	20	10	0	0	20	10
	40	0	10	10	40	0	10	10
Mean	20	2	16	16	20	2	16	16
5.4% RT HES-1:10 +Lazaroid	20	0	20	10	20	0	10	10
	20	0	10	10	20	0	20	10
	30	0	30	20	30	0	30	20**
	0	10	20	10	0	10	20	10
	20	0	30	10	20	0	30	10**
Mean	18	2	22	12	18	2	22	12
5.4% 4C HES-1:10	30	10	10	10	30	10	20	10**
	60	40	30	30	60	40	20	30
	0	30	30	0	0	30	20	0
	0	20	20	10	0	20	20	10
	20	0	20	0	20	0	30	0+
Mean	22	20	22	10	22	20	22	10
5.4% 4C HES-1:10 +Lazaroid	0	20	20	20	0	20	0	20
	0	20	10	0	0	20	0	0
	10	0	10	0	10	0	20	0
	20	0	10	10	20	0	10	10**
	10	0	20	20	10	0	20	20**
Mean	8	8	14	10	8	8	10	10
Lazaroid (Fresh)	20	0	20	20	20	0	20	20
	30	0	20	10	30	0	20	10
	10	0	10	0	10	0	10	0
	0	0	10	10	0	0	10	10
	50	20	20	10	50	20	20	10+
Mean	22	4	16	10	22	4	16	10
Lazaroid (Stored)	20	0	20	10	20	0	20	10

+ Organ with incision

** Material present

RT = HES-1:10 stored at room temperature, any viscosity due to concentration of HES-1:10.

4C = HES-1:10 stored in a refrigerator, this increases viscosity.

TABLE 6 (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Mean	10	0	20	10	10	0	20	10
	10	20	20	0	10	20	30	0
	20	0	10	0	20	0	10	0
	20	0	10	10	20	0	10	10
	16	4	16	6	16	4	18	6

[0053] Statistical analysis was performed on the overall score of the nonparametric data taken from Table 5. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below. Comparison of the rank order of 8.1% RT HES-1:10 with 8.1% RT HES-1:10 + Lazaroid gave a p value of 0.019, 8.1% 4C HES-1:10 with 8.1% 4C HES-1:10 + Lazaroid gave a p value of 0.000, 5.4% RT HES-1:10 with 5.4% RT HES-1:10 + Lazaroid gave a p value of 0.042 and 8.1% 4C HES-1:10 + Lazaroid with lazardoid gave a p value of 0.030.

Treatment	Rank order	p value
Control	90.6 ± 6.6	--
13.5% RT HES-1:10	47.5 ± 13.0	0.000
13.5% RT HES-1:10 + lazardoid	39.6 ± 22.8	0.000
13.5% 4C HES-1:10	41.0 ± 0.00	0.000
13.5% 4C HES-1:10 + lazardoid	57.3 ± 20.6	0.000
10.8% RT HES-1:10	59.2 ± 33.9	0.012
10.8% RT HES-1:10 + lazardoid	35.5 ± 23.3	0.000
10.8% 4C HES-1:10	60.5 ± 15.9	0.000
10.8% 4C HES-1:10 + lazardoid	36.0 ± 30.6	0.000
Stored lazardoid	48.0 ± 23.5	0.000
8.1% RT HES-1:10	63.3 ± 21.7	0.002
8.1% RT HES-1:10 + lazardoid	29.0 ± 14.7	0.000
8.1% 4C HES-1:10	70.3 ± 16.0	0.004
8.1% 4C HES-1:10 + lazardoid	17.0 ± 12.0	0.000
5.4% RT HES-1:10	51.3 ± 27.7	0.000
5.4% RT HES-1:10 + lazardoid	47.5 ± 13.0	0.000
5.4% 4C HES-1:10	59.3 ± 23.9	0.002
5.4% 4C HES-1:10 + lazardoid	29.0 ± 14.7	0.000
Fresh lazardoid	45.3 ± 32.1	0.000

Example 5: Further Evaluation of HES-1:10 Compositions

[0054] In this Example, various volumes of a HES-1:10 composition were evaluated in the rabbit double uterine horn model for adhesion prevention. The composition was administered in a volumes of 5, 10, 15, and 20 ml at the end of surgery and the animals were sacrificed at day 7. Two sets of experiments were performed using either saline or phosphate buffered saline vehicles. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 7 and 7a (phosphate buffered saline vehicle) and Tables 8 and 8a (saline vehicle). HES-1:10 alone was found to be efficacious in reducing adhesions in the rabbit double uterine horn model.

TABLE 7

HES-1:10 (in 1/10 PBS) Volume Response	
Treatment	Overall Adhesion Score
Surgical Control	2+
	3.5+
	1.5+
	3+
	3+
	3.5+
	1.5+
5 ml RT HES-1:10	3.5+
	1+
	1.5+
	1.5+
	2.5+
	1+
	1.5+
10 ml RT HES-1:10	2.5+
	2+
	2+
	2+
	1+
	1+
	1+
15 ml RT HES-1:10	1+
	2+
	1.5+
	2.5+
	2+
	1+
	1+
20 ml RT HES-1:10	1+
	1.5+
	1+
	1.5+
	2+
	1.5+
	1.5+
5 ml 4C HES-1:10	2+
	2+
	1+
	2.5+
	2+
	1.5+
	1+

EP 0 831 856 B1

TABLE 7 (continued)

HES-1:10 (in 1/10 PBS) Volume Response	
Treatment	Overall Adhesion Score
10 ml 4C HES-1:10	1.5+
	1.5+
	1.5+
	1.5+
	1.5+
	1.5+
15 ml 4C HES-1:10	3+
	1.5+
	1.5+
	1+
	2+
	1.5+
20 ml 4C HES-1:10	1+
	2+
	2+
	0.5+
	2+
	1.5+
	2+
	1.5+
	1.5+

TABLE 7a

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	20	0	30	20	20	0	20	20
	40	50	30	30	40	50	40	30*
	30	0	10	10	30	0	10	10
	40	10	30	30	40	10	40	30
	30	20	30	40	30	20	30	40*
	50	30	30	20	50	30	30	20
	0	10	10	10	0	10	10	10
	30	50	30	40	30	50	30	40
Mean	30	21.3	25	25	30	21.3	26.3	25
5 ml RT HES-1:10	20	0	10	0	20	0	10	0
	30	0	10	20	30	0	10	20
	30	0	20	0	30	0	20	0
	20	10	20	20	20	10	20	20
	10	0	10	0	10	0	20	0

* Organ with incision

RT = HES-1:10 stored at room temperature, any viscosity due to concentration of HES-1:10

4C = HES-1:10 stored in a refrigerator, this increase viscosity

EP 0 831 856 B1

TABLE 7a (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Mean	10	0	10	10	10	0	10	10
	30	10	10	40	30	10	20	40
	21.4	2.9	12.9	12.9	21.4	2.9	15.7	12.9
10 ml RT HES-1:10	20	20	10	0	20	20	40	0
	20	20	10	10	20	20	20	10
	0	30	30	30	0	30	30	30
	0	20	10	0	0	20	10	0
	0	0	10	10	0	0	20	10
	20	0	20	0	20	0	20	0
	0	0	10	10	0	0	10	10+
Mean	8.6	12.9	14.3	7.1	8.6	12.9	21.4	7.1
15 ml RT HES-1:10	0	10	10	0	0	10	10	0
	0	70	10	0	0	70	20	0
	0	10	10	10	0	10	10	10
	20	20	20	10	20	20	20	10
	30	10	10	10	30	10	10	10*
	0	10	10	0	0	10	10	0
	0	10	20	0	0	10	20	0
Mean	7.1	20	12.9	4.3	7.1	20	14.3	4.3
20 ml RT HES-1:10	0	20	20	10	0	20	20	10
	10	0	20	0	10	0	20	0
	0	10	30	10	0	10	30	10
	30	20	20	0	30	20	20	0
	10	0	20	10	10	0	20	10
	10	10	10	10	10	10	0	10
	20	10	20	20	20	10	20	20+
Mean	11.4	10	20	8.6	11.4	10	18.6	8.6
5 ml 4C HES-1:10	20	0	20	20	20	0	20	20
	10	20	0	0	10	20	10	0
	20	30	20	10	20	30	20	10+
	30	20	20	0	30	20	20	0+
	20	10	20	10	20	10	20	10
	10	0	10	0	10	0	10	0
	30	0	20	0	30	0	20	0
Mean	20	11.4	15.7	5.7	20	11.4	17.1	5.7
10 ml 4C HES-1:10	10	0	20	10	10	0	20	10
	20	0	20	20	20	0	20	20
	10	0	20	20	10	0	20	20

* Organ with incision

+ Material present

RT = HES-1:10 stored at room temperature, any viscosity due to concentration of HES-1:10

4C = HES-1:10 stored in a refrigerator, this increase viscosity

EP 0 831 856 B1

TABLE 7a (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Mean	10	10	10	0	10	10	10	0
	10	10	10	10	10	10	10	10
	0	10	10	10	0	10	10	10
	40	20	20	20	40	20	20	20
	14.3	7.1	15.7	12.9	14.3	7.1	15.7	12.9
15 ml 4C HES-1:10	0	20	10	10	0	20	10	10
	0	10	10	20	0	10	10	20
	10	0	10	0	10	0	10	0
	30	0	20	10	30	0	20	10
	20	0	10	10	20	0	10	10+
Mean	10	0	10	0	10	0	10	0
	50	10	10	10	50	10	10	10
	17.1	5.7	11.4	8.6	17.1	5.7	11.4	8.6
20 ml 4C HES-1:10	20	10	20	10	20	10	20	10
	0	0	20	0	0	0	20	0
	10	10	20	20	10	10	20	20
	30	0	0	20	30	0	20	20
	30	0	20	20	30	0	20	20+
Mean	20	10	20	0	20	10	10	0
	20	20	20	10	20	20	20	10
	18.6	7.1	17.1	11.4	18.6	7.1	18.6	11.4

+ Material present

RT = HES-1:10 stored at room temperature, any viscosity due to concentration of HES-1:10

4C = HES-1:10 stored in a refrigerator, this increase viscosity

TABLE 8

HES (10%) in Saline Volume Response	
Treatment	Overall Score
Surgical Control	2.5+
	3+
	2.5+
	2.5+
	2.5+
	3+
	2.5+
5 ml RT HES-1:10	3+
	1.5+
	1.5+
	2+
	1.5+
	1.5+
	1.5+
10 ml RT HES-1:10	2+
	1.5+

EP 0 831 856 B1

TABLE 8 (continued)

HES (10%) in Saline Volume Response	
Treatment	Overall Score
5	1.5+
	1.5+
	2+
	1.5+
	2+
10	2.5+
	15 ml RT HES-1:10
	1+
	1.5+
	1.5+
15	2+
	2+
	2+
	1.5+
	20 ml RT HES-1:10
20	1.5+
	1.5+
	1.5+
	1.5+
	0.5+
25	1.5+
	1.5+
	5 ml 4C HES-1:10
	1+
	1.5+
30	2+
	1.5+
	2+
	1.5+
	2+
35	10 ml 4C HES-1:10
	1+
	2+
	2+
	2+
40	2+
	1.5+
	15 ml 4C HES-1:10
	2+
	2.5+
45	2+
	Died
	1.5+
	1+
	2+
50	20 ml 4C HES-1:10
	2.5+

55

EP 0 831 856 B1

TABLE 8 (continued)

HES (10%) in Saline Volume Response	
Treatment	Overall Score
	2+
	1.5+
	1.5+
	1.5+
	1.5+
	2.5+

TABLE 8a

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	20	30	20	10	20	30	20	10
	30	30	30	30	30	30	30	30
	30	30	30	30	30	30	20	30+
	30	30	30	20	30	30	20	20
	0	30	30	10	0	30	40	30
	40	30	40	30	40	30	40	30
	20	40	20	20	20	40	30	20+
	30	30	40	30	30	30	40	30
Mean	25	31.3	30	22.5	25	31.3	30	22.5
5 ml RT HES-1:10	10	0	10	20	10	0	20	20
	20	0	10	0	20	0	10	0+
	20	10	10	10	20	10	10	10+
	10	0	20	20	10	0	10	20
	20	0	20	20	20	0	20	20
	0	20	30	10	0	20	30	10+
	0	30	10	20	0	30	20	20
	11.4	8.6	15.7	14.3	11.4	8.6	17.1	14.3
10 ml RT HES-1:10	10	10	20	10	10	10	10	10
	20	20	20	0	20	20	10	0
	0	20	20	10	0	20	10	10*
	30	0	20	20	30	0	20	20
	10	0	20	30	10	0	20	30
	30	10	20	20	30	10	10	20
	50	20	20	10	50	20	20	10
	21.4	11.4	20	14.3	21.4	11.4	14.3	14.3
15 ml RT HES-1:10	10	0	20	0	10	0	20	0
	20	0	10	10	20	0	10	10
	10	10	10	0	10	10	0	0

+ Organ with Incision

* Material Present

RT = HES stored at room temperature, any viscosity due to concentration of HES

4C = HES stored in a refrigerator, this increase viscosity

EP 0 831 856 B1

TABLE 8a (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	20	10	20	10	20	10	20	10*
	30	10	20	20	30	10	20	20+
	30	10	20	10	20	10	20	10*
	20	10	10	10	0	10	10	10
	15.7	7.1	15.7	8.6	15.7	7.1	14.3	8.6
20 ml RT HES-1:10	20	0	10	20	20	0	10	20
	10	10	20	0	10	10	20	0
	20	0	20	0	20	0	30	0
	0	10	30	10	0	10	20	10
	0	0	10	0	0	0	20	0
Mean	10	0	10	20	10	0	10	20*
	20	0	10	10	20	0	10	10
	11.4	2.9	15.7	8.6	11.4	2.9	17.1	8.6
	5 ml 4C HES-1:10	10	0	0	10	0	20	10
	10	10	30	0	10	10	20	0*
25	10	0	30	30	10	0	30	30*
	10	0	20	10	10	0	20	10
	30	0	40	20	30	0	30	20*
	20	0	20	10	20	0	20	10*
	20	20	20	30	20	20	20	30
Mean	15.7	4.3	22.9	15.7	15.7	4.3	22.9	15.7
	10 ml 4C HES-1:10	10	0	20	0	10	0	0
	10	10	20	20	10	10	20	20*
	20	10	20	0	20	10	20	0
	0	20	20	20	0	20	30	20*
35	10	10	10	20	10	10	20	20
	0	10	20	10	0	10	20	10*
	10	11.4	18.6	12.9	10	11.4	21.4	12.9
	15 ml 4C HES-1:10	20	0	20	30	20	0	20
	40	10	20	30	40	10	10	30*
45	10	10	20	30	10	10	20	30
	0	10	10	10	0	10	10	10*
	0	0	20	10	0	0	20	10
	20	20	20	10	20	20	20	10*
	Mean	15	8.3	18.3	20	15	8.3	16.7
50	20 ml 4C HES-1:10	20	0	20	30	20	0	20
	20	10	20	10	20	10	20	30*
								10*

+ Organ with Incision

* Material Present

RT = HES stored at room temperature, any viscosity due to concentration of HES

4C = HES stored in a refrigerator, this increase viscosity

EP 0 831 856 B1

TABLE 8a (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
	0	20	10	10	0	20	10	10+,*
	0	20	10	10	0	20	10	10*
	0	10	10	10	0	10	10	10
	0	20	20	20	0	20	20	20*
	30	0	20	20	30	0	10	20+,*
Mean	10	11.4	15.7	15.7	10	11.4	14.3	15.7

+ Organ with Incision

* Material Present

RT = HES stored at room temperature, any viscosity due to concentration of HES

4C = HES stored in a refrigerator, this increase viscosity

[0055] Statistical analysis was performed on the overall score of the nonparametric data taken from Tables 7 and 8. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below.

TABLE 7

ANALYSIS		
Treatment	Rank order	p value
Control	51.4 ± 14.6	--
5 ml RT HES-1:10	30.4 ± 18.3	0.028
10 ml RT HES-1:10	25.0 ± 19.1	0.001
15 ml RT HES-1:10	29.1 ± 19.5	0.025
20 ml RT HES-1:10	30.4 ± 12.3	0.011
5 ml 4C HES-1:10	31.8 ± 17.7	0.035
10 ml 4C HES-1:10	32.1 ± 11.4	0.014
15 ml 4C HES-1:10	27.6 ± 15.6	0.009
20 ml 4C HES-1:10	32.1 ± 15.6	0.028

TABLE 8

ANALYSIS		
Treatment	Rank order	p value
Control	58.3 ± 2.9	--
5 ml RT HES-1:10	25.6 ± 10.39	0.000
10 ml RT HES-1:10	30.9 ± 14.36	0.000
15 ml RT HES-1:10	26.6 ± 14.23	0.000
20 ml RT HES-1:10	16.4 ± 6.30	0.000
5 ml 4C HES-1:10	26.6 ± 14.23	0.000
10 ml 4C HES-1:10	33.2 ± 14.50	0.000
15 ml 4C HES-1:10	34.1 ± 17.47	0.002
20 ml 4C HES-1:10	32.9 ± 16.57	0.000

Example 6: Side Wall Model Evaluation of Betamethasone

[0056] The efficacy of betamethasone in preventing adhesion formation was evaluated in the sidewall model. The drug was delivered for 7 days at a rate of 10 µl/hr and the animals were sacrificed after 7 days. The vehicle was saline. Relative to the control, betamethasone was efficacious in the sidewall model at the doses tested. Four of the treated

rabbits had accumulation of fluid subcutaneously. The results are summarized in Table 9. A student t test analysis of the data was performed and the results are reported in Table 9 as well.

TABLE 9

Betamethasone Sidewall Model		
Treatment	% Adhesions	Adhesion Score
Vehicle Control	70%	2+
	0%	0
	90%	3+
	100%	2+
	100%	2+
	90%	2+
Mean:	75.0% ± 35.0	
5.0 mg/ml Betamethasone in Vehicle	0%	0+*
	0%	0+
	0%	0+**
	0%	0+
	0%	0+
Died d3 P/O		
Mean ^a :	0.0% ± 0.0	
0.5 mg/ml Betamethasone in Vehicle	0%	0+
	0%	0+
	0%	0+***
	10%	1+
	100%	1+*
Mean ^b :	0%	0+*
	18.3% ± 36.7	

* Sidewall was Inflamed

** Bleeding Intraperitoneally

*** White precipitate

a p = 0.000

b p = 0.021

Example 7: Double Uterine Horn Evaluation of Betamethasone

[0057] In this Example, compositions containing 0.5 mg/ml and 5.0 mg/ml betamethasone sodium phosphate (Sigma Chemical Co., St. Louis, MO, USA) in saline were evaluated in the rabbit uterine horn model for adhesion prevention. The composition was administered via Alzet miniosmotic pump for 7 days at a rate of 10 ul/hour. The animals were sacrificed at day 7. The vehicle control is saline. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 10 and 11. Betamethasone was found to be highly efficacious in the reduction of adhesion formation in the double uterine horn model.

TABLE 10

Betamethasone DUH Model	
Treatment	Overall Adhesion Score
Vehicle Control	3.5+
	2.5+
	3+

EP 0 831 856 B1

TABLE 10 (continued)

Betamethasone DUH Model	
Treatment	Overall Adhesion Score
5.0 mg/ml Betamethasone	2.5+
	3.5+
	3+
	0.5+
	1.0+
0.5 mg/ml Betamethasone	1.0+
	1.5+
	1.5+
	Infection
	0.5+
	1+
	1.5+
	1.5+
	0.5+
	1+

TABLE 11

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	100	0	50	100	100	0	50	100
	30	30	60	30	30	30	30	30
	40	30	60	50	40	30	50	50**
	30	30	30	40	30	30	30	40
	30	100	40	0	30	100	50	0
	40	60	30	0	40	60	30	0
Mean	45	41.7	45	36.7	45	41.7	40	36.7
5.0 mg/ml Betamethasone	0	0	0	10	0	0	0	10
	0	0	30	0	0	0	20	0
	0	0	0	10	0	0	10	10
	0	20	0	20	0	0	0	20
	10	10	20	10	10	10	0	10
INFECTION								
Mean	2	6	10	10	2	2	6	10
0.5 mg/ml Betamethasone	0	0	0	10	0	0	0	10

** Horn and bowel or bladder to sidewall

TABLE 11 (continued)

% Organ Involvement in Uterine Horn Adhesion								
INFECTION								
	0	0	10	20	0	0	0	20*
	0	10	10	10	10	10	0	10
	20	10	10	10	20	10	10	10*
	0	0	10	0	0	0	0	0
	0	10	20	0	0	10	0	0
Mean	3.3	5	10	8.3	5	5	1.7	8.3

* Bladder, horn or bowel adhered to the sidewall (at either tube or tube suture)

[0058] Statistical analysis was performed on the overall score of the nonparametric data taken from Table 10. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below.

Treatment	Rank order	p value
Control	14.5 ± 1.63	--
5 mg/ml Betamethasone	6.4 ± 2.84	0.000
0.5 mg/ml Betamethasone	5.8 ± 3.06	0.000

Example 8: Kinetic Evaluation of Betamethasone

[0059] The efficacy of betamethasone in the double uterine horn model was further evaluated in a kinetics study. In this study, the pump was disconnected at various times after surgery to determine the time period of exposure to the drug effective to reduce adhesion formation. The results are summarized in Tables 12 and 13.

TABLE 12

Treatment	Overall Adhesion Score
Vehicle Control	3+
	2.5+
	3+
	2.5+
	3.5+
	2+
5 mg/ml Betamethasone 24 hour D/C	0.5+
	1+
	1+
	1+
	Died
	1.5+
5 mg/ml Betamethasone 48 hour D/C	1+
	1+
	1.5+
	1.5+
	1.5+
	1+

TABLE 12 (continued)

Treatment	Overall Adhesion Score
5 mg/ml Betamethasone 72 hour D/C	1.5+
	1+
	0.5+
	1+
	1+
	2.5+
0.5 mg/ml Betamethasone 24 hour D/C	Infection
	0.5+
	1.5+
	0.5+
	Died
	1+
0.5 mg/ml Betamethasone 48 hr D/C	1.5+
	2+
	1+
	0.5+
	1.5+
	1+
0.5 mg/ml Betamethasone 72 hour D/C	0.5+
	1.5+
	1.5+
	1.5+
	Died
	1+

TABLE 13

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	20	60	40	20	20	60	30	20*
	30	40	20	0	30	40	40	0*
	20	40	40	40	20	40	20	40**
	50	30	30	50	50	30	30	50
	20	100	50	20	20	100	30	40
	0	40	10	20	0 0	40	0	20
Mean	23.3	51.7	31.7	28.3	23.3	51.7	25.7	28.3

* Bladder, horn or bowel adhered to the sidewall (at either tube or tube suture)

** Horn and bowel or bladder to sidewall

EP 0 831 856 B1

TABLE 13 (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
5 mg/ml Betamethasone 24 D/C	0	0	10	10	0	0	10	10
	0	10	10	0	0	10	10	0*
	0	0	10	10	0	0	0	10
	0	0	10	10	0	0	10	10*
Died P/O								
Mean	10	0	30	0	10	0	30	0 ^b
	2	2	14	6	2	2	10	6
5 mg/ml Betamethasone 48 hr D/C	0	0	10	20	0	10	10	20
	0	0	10	0	0	0	10	0*
	0	10	20	10	0	10	20	10
	0	0	30	20	0	0	1	20*
	10	0	0	0	0	20	30	0*
Mean	0	0	10	20	0	0	10	20
	1.7	1.7	13.3	11.7	0	6.7	15	11.7
5 mg/ml Betamethasone 72 hr D/C	0	30	20	10	0	30	20	10
	0	0	20	10	0	0	0	10 ^b
	0	0	10	0	0	0	0	0
	0	0	10	20	0	0	10	20
	0	0	10	10	0	0	10	10 ^a
	40	10	10	10	40	10	10	10*
Mean	6.7	6.7	13.3	10	6.7	6.7	8.3	10
0.5 mg/ml Betamethasone 24 hr D/C	Bleeding and Infection							
	0	0	10	0	0	0	10	0
	10	0	20	10	10	0	0	10
	0	0	10	0	0	10	0	0
DIED P/O								
Mean	0	0	0	10	0	0	10	0
	2.5	0	10	5	2.5	2.5	5	5
0.5 mg/ml Betamethasone 48 hr D/C	0	10	20	10	0	0	30	10*
	30	0	10	20	30	0	10	20
	0	0	10	10	0	0	10	10
	0	0	20	0	0	0	20	0 ^b
	0	30	20	0	0	30	20	0
	0	10	10	0	0	10	0	0
Mean	5	8.3	15	6.7	5	6.7	15	6.7

* Bladder, horn or bowel adhered to the sidewall (at either tube or tube suture)

^b Ascites noted

TABLE 13 (continued)

% Organ Involvement in Uterine Horn Adhesion								
	DIED P/O							
0.5mg/ml Betamethasone 72 hr D/C	0	0	0	0	0	0	20	0
	0	30	10	10	0	10	0	10
	0	0	10	10	0	0	30	10 ^a
	0	20	30	0	0	20	10	0
	DIED P/O							
Mean	0	20	10	30	0	20	10	30 ^a
	0	10	12	10	0	10	14	10

^a Intraperitoneal bleeding

[0060] Statistical analysis was performed on the overall score of the nonparametric data taken from Table 12. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below.

Treatment	Rank order	p value
Control	35.1 ± 2.15	--
5 mg/ml betamethasone 24 hour D/C	13.5 ± 6.83	0.000
5 mg/ml betamethasone 48 hour D/C	19.0 ± 6.00	0.000
5 mg/ml betamethasone 72 hour D/C	16.9 ± 9.86	0.001
0.5 mg/ml betamethasone 24 hour D/C	11.3 ± 8.84	0.000
0.5 mg/ml betamethasone 48 hour D/C	18.5 ± 9.48	0.002
0.5 mg/ml betamethasone 72 hour D/C	18.3 ± 8.74	0.001

Example 9: Evaluation of HES-1:10/betamethasone Compositions

[0061] In this Example, 10.8% (w/v) or 13.5% (w/v) HES-1:10 compositions alone or in combination with (0.5 mg/ml) betamethasone, a synthetic corticosteroid, were evaluated for adhesion prevention. The composition was administered at the end of surgery in a volume of 5 ml and the animals were sacrificed at day 7. The control was surgery only. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 14 and 15. HES-1:10 alone and in combination with betamethasone was efficacious at the reduction of adhesions in the rabbit double uterine horn model.

TABLE 14

HES-1:10 + Betamethasone	
Treatment	Overall Score
Surgical Control	3+ 3+ 2+ 3.5+ 2.5+
13.5% RT HES-1:10	1.5+ 1.5+ 1.5+ 1.5+

EP 0 831 856 B1

TABLE 14 (continued)

HES-1:10 + Betamethasone	
Treatment	Overall Score
13.5% RT HES-1:10 + Betamethasone	1.5+
	1.5+
	1+
	1+
13.5% 4C HES-1:10	1+
	1+
	1+
	1+
13.5% 4C HES-1:10 + Betamethasone	Sac D1 P/O
	1.5+
	2+
	1+
10.8% RT HES-1:10	1+
	1.5+
	2.5+
	0.5+
10.8% RT HES-1:10 + Betamethasone	1+
	2+
	1.5+
	1.5+
10.8% 4C HES-1:10	2+
	1+
	1.5+
	2.5+
10.8% 4C HES-1:10 + Betamethasone	1.5+
	1.5+
	1.5+
	1.5+

EP 0 831 856 B1

TABLE 14 (continued)

HES-1:10 + Betamethasone	
Treatment	Overall Score
0.5 mg/ml Betamethasone	1.5+
	1.5+
	1+
	1+
	2+
	1.5+
	1.5+

TABLE 15

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	40	20	30	40	40	20	30	40
	40	30	40	50	40	30	40	50
	0	30	30	0	0	30	30	0
	40	50	40	40	40	50	20	40
	0	40	20	0	0	40	20	0
Mean	24	34	32	26	24	34	28	26
13.5% RT HES-1:10	0	30	20	0	0	30	20	0
	0	30	20	0	0	30	20	0
	0	30	20	0	0	30	20	0
	10	0	20	10	0	10	20	10
	0	20	20	10	0	20	20	10
Mean	2	22	20	4	0	24	20	4
13.5% RT HES-1:10 + betamethasone	0	20	20	0	0	20	20	0
	10	0	10	0	0	0	10	0
	0	0	20	10	0	0	20	10
	0	10	10	0	0	10	20	0
	0	0	20	10	0	0	20	10
Mean	2	6	16	4	0	6	18	4
SACRIFICED DI								
13.5% 4C HES-1:10	20	0	10	10	20	0	20	10
	10	30	10	0	10	30	10	0
	0	0	0	30	0	0	20	30+
	0	10	30	0	0	10	20	0
	7.5	10	12.5	10	7.5	10	17.5	10
Mean	7.5	10	12.5	10	7.5	10	17.5	10
13.5% 4C HES-1:10 + betamethasone	0	10	20	10	0	0	0	10
	0	0	10	0	0	0	10	0

EP 0 831 856 B1

TABLE 15 (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Mean	0	0	20	0	0	0	10	0
	0	0	10	10	0	0	10	10
	0	0	20	30	0	0	20	30
	0	2	16	10	0	0	10	10
10.8% RT HES-1:10	10	0	30	0	10	0	20	0
Mean	30	30	20	20	30	30	30	20
	0	0	20	0	0	0	20	0+
	0	0	20	10	0	0	20	10
	20	0	20	10	20	0	20	10
10.8% RT HES-1:10 + betamethasone	12	6	22	8	12	6	22	8
Mean	0	0	30	30	0	0	20	30+
	10	0	10	0	0	0	10	0
	0	30	30	20	0	30	30	20
	20	0	10	10	20	0	10	10
10.8% 4C HES-1:10	40	0	20	20	40	0	20	20+
Mean	0	10	10	0	0	10	10	0
	0	20	20	0	0	20	20	0
	40	30	20	20	40	30	20	20
	0	10	20	0	0	10	20	0
10.8% 4C HES-1:10 + betamethasone	16	14	18	8	16	14	18	8
Mean	0	20	20	0	0	20	20	0
	0	20	20	0	0	20	20	0
	10	0	20	10	10	0	20	10
	0	20	20	0	0	20	20	0
Betamethasone	2	16	20	4	2	16	20	4
Mean	0	0	20	10	0	0	10	10
	0	0	20	0	0	10	20	0
	20	10	20	0	20	20	20	0
	10	0	20	30	10	0	20	30
Mean	0	30	20	0	0	30	20	0
	6	10	20	8	6	12	18	8

+ Material present on horns

[0062] Statistical analysis was performed on the overall score of the nonparametric data taken from Table 14. The

data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below. Comparison of the rank order of 13.5% RT HES-1:10 with 13.5% RT HES-1:10 + betamethasone gave a p value of 0.001.

Treatment	Rank order	p value
Control	45.8 ± 3.2	--
13.5% RT HES-1:10	26.0 ± 0.0	0.000
13.5% RT HES-1:10 + betamethasone	12.8 ± 6.0	0.000
13.5% 4C HES-1:10	21.3 ± 12.8	0.003
13.5% 4C HES-1:10 + betamethasone	15.9 ± 14.9	0.002
10.8% RT HES-1:10	24.5 ± 16.7	0.023
10.8% RT HES-1:10 + betamethasone	25.5 ± 9.7	0.021
10.8% 4C HES-1:10	29.3 ± 12.5	0.021
10.8% 4C HES-1:10 + betamethasone	26.0 ± 0.0	0.000
Betamethasone	22.2 ± 11.6	0.002

Example 10: Evaluation of HES-1:10/betamethasone Composition

[0063] In this Example, 8.1% (w/v) and 5.4% (w/v) HES-1:10 compositions alone or in combination with 0.5 mg/ml betamethasone were evaluated in the double uterine horn model for adhesion prevention. The composition was administered at the end of surgery in a volume of 5 ml and the animals were sacrificed at day 7. One control was treated with saline vehicle (termed saline on the table) and the other had surgery only (surgical control). The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 16 and 17. HES-1:10 alone or in combination with betamethasone was efficacious at the reduction of adhesions in the rabbit double uterine horn model.

TABLE 16

HES-1:10 + Betamethasone	
Treatment	Overall Score
Surgical Control	3+ 3+ Died 3+ 3+
8.1% RT HES-1:10	2+ 1.5+ 1.5+ 2+ 2+
8.1% RT HES-1:10 + Betamethasone	0.5+ 1+ 1.5+ 1+ 1+
8.1% 4C HES-1:10	1+ 1+ Died 1.5+

TABLE 16 (continued)

HES-1:10 + Betamethasone	
Treatment	Overall Score
8.1% 4C HES-1:10 + Betamethasone	1.5+
	1+
	1.5+
	2+
	2+
5.4% RT HES-1:10	1+
	2+
	1.5+
	1.5+
	1.5+
5.4% RT HES-1:10 + Betamethasone	1.5+
	1.5+
	1+
	2+
	0.5+
5.4% 4C HES-1:10	1.5+
	1+
	Died
	2+
	1+
5.4% 4C HES-1:10 + Betamethasone	1.5+
	1+
	2+
	1+
	1.5+
Saline	2+
	2.5+
	2.5+
	2+
	3+

TABLE 17

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Surgical Control	50	40	30	20	50	40	40	20
	30	40	40	20	30	40	30	20
	DIED							
	30	40	40	30	30	40	30	30
	40	20	20	30	40	20	30	30

EP 0 831 856 B1

TABLE 17 (continued)

% Organ Involvement in Uterine Horn Adhesion									
		DIED							
5	Mean	37.5	28	32.5	25	37.5	28	32.8	25
	8.1 % RT HES-1:10	10	40	0	0	10	40	10	0
10		10	0	10	10	10	0	10	10
		0	10	20	10	0	10	20	10
		20	20	20	0	20	20	20	0
		10	10	20	10	10	10	10	10
	Mean	10	16	14	6	16	14	14	6
15	8.1% RT HES-1:10 + Betamethasone	0	0	10	0	0	0	10	0
		0	20	20	0	0	20	20	0
20		0	10	30	10	0	10	20	10
		0	10	10	0	0	10	10	0+
		30	0	0	0	30	0	20	0
	Mean	6	8	14	2	6	8	16	2
25	8.1 % 4C HES-1:10	0	0	10	10	0	0	20	10+
		0	0	20	20	0	0	10	20+
		0	20	20	0	0	20	10	0
30		DIED							
	Mean	30	0	20	20	30	0	20	20
		7.5	4	17.5	12.5	7.5	4	15	12.5
35	8.1% 4C HES-1:10 + Betamethasone	20	0	10	0	20	0	20	0
		0	10	20	10	0	10	20	10
		10	30	20	0	10	30	10	0
		20	30	20	0	20	30	20	0
40		0	10	20	0	0	10	10	0
	Mean	10	16	18	2	10	16	16	2
	5.4% RT HES-1:10	20	0	20	20	20	20	20	20
45		10	20	20	0	10	20	0	0
		20	0	10	10	20	0	20	10
		0	10	30	20	0	10	10	20
		10	10	10	0	10	10	10	0
50	Mean	12	8	18	10	12	12	12	10
	5.4% RT HES-1:10 + Betamethasone	0	10	30	10	0	10	10	10
		10	0	20	20	0	0	20	20
55		0	0	20	10	0	0	10	10
		0	20	20	10	0	20	20	10
		0	0	20	0	0	0	20	0

TABLE 17 (continued)

% Organ Involvement in Uterine Horn Adhesion									
	DIED								
Mean	2	6	22	10	0	6	16	10	
5.4% 4C HES-1:10	0	30	20	0	0	30	20	0	
	0	10	20	0	0	10	20	0	
	DIED								
Mean	30	0	20	0	30	0	20	0	
	0	10	20	0	0	10	20	0	
	7.5	12.5	20	0	7.5	12.5	20	0	
	5.4% 4C HES-1:10 + Betamethasone	10	0	20	20	10	0	20	20
	0	0	20	20	0	0	10	20	
	0	30	20	0	0	30	20	0	
	0	0	10	10	0	0	10	10	
	0	10	20	10	0	10	20	10	
Mean	2	8	18	12	2	8	16	12	
Saline	20	20	20	20	20	20	20	20	
	10	30	20	10	10	30	40	10	
	20	40	20	40	20	40	20	40	
	20	30	20	0	20	30	30	0	
	20	80	30	0	20	80	20	0	
Mean	18	40	22	14	15	40	26	145	
+ Material present on horns									

[0064] Statistical analysis was performed on the overall score of the nonparametric data taken from Table 16. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below. Comparison of the rank order of 8.1% RT HES-1:10 with 8.1% RT HES-1:10 + betamethasone gave a p value of 0.001.

Treatment	Rank order	p value
Control	45.0 ± 0.0	--
8.1% RT HES-1:10	29.8 ± 6.4	0.000
8.1% RT HES-1:10 + betamethasone	9.8 ± 6.7	0.000
8.1% 4C HES-1:10	15.3 ± 6.8	0.000
8.1% 4C HES-1:10 + betamethasone	21.8 ± 11.9	0.002
5.4% RT HES-1:10	24.6 ± 5.2	0.000
5.4% RT HES-1:10 + betamethasone	17.8 ± 11.7	0.000
5.4% 4C HES-1:10	18.5 ± 11.0	0.000
5.4% 4C HES-1:10 + betamethasone	19.2 ± 9.9	0.000
Saline	39.6 ± 4.0	0.017

Example 11: Evaluation of Hetastarch Compositions

[0065] In this Example, various concentrations of hetastarch (HES-7-8:10) compositions were evaluated in the rabbit double uterine horn model for adhesion prevention. Hetastarch compositions having concentrations of 16.2%, 13.5%, 10.8%, 8.1%, and 5.4% (w/v) (Tables 18 and 18a) were administered in 15 ml and 40.0%, 34.3%, 28.5%, 23.5%, 18.6%, 16.2% and 13.5% (w/v) (Tables 19 and 19a) were administered in 5 ml at the end of surgery and the animals were sacrificed at day 7. The surgical control received no composition. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 18, 18a,

EP 0 831 856 B1

19 and 19a. HES-7-8:10 alone was found to be efficacious at the concentrations tested in reducing adhesions in the rabbit double uterine horn model.

TABLE 18

Treatment	Overall Score
Surgical Control	3+
	3+
	2.5+
	2.5+
	3+
16.2% (w/v) Hetastarch	2+
	2+
	2.5+
	2.5+
	2+
13.5% Hetastarch	1.5+
	2+
	1.5+
	1.5+
	1.5+
10.8% Hetastarch	1.5+
	1.5+
	1.5+
	1.5+
	1.5+
8.1% Hetastarch	1.5+
	1.5+
	1.5+
	2+
	1+
5.4% Hetastarch	2+
	1+
	1.5+
	1.5+
	2+

TABLE 18a

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	50	60	20	10	50	60	20	10
	20	60	20	20	20	60	20	20
	20	40	10	30	20	40	20	30
	10	30	30	30	10	30	20	30
	20	50	20	20	20	50	20	20

TABLE 18a (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Mean	24	48	20	22	24	48	20	22
16.2% (w/v) Hetastarch	30	10	10	10	30	10	10	10
	10	30	30	30	10	30	20	30
	30	30	20	30	30	30	20	30
	30	20	10	10	30	20	20	10+
	50	0	20	0	50	0	20	0
Mean	30	18	18	16	30	18	18	16
13.5% Hetastarch	10	0	30	20	10	0	30	20
	30	20	10	10	30	20	20	10
	20	0	30	10	20	0	20	10
	0	0	10	10	0	0	20	10
	20	10	10	0	20	10	20	0
Mean	16	6	18	10	16	6	22	10
10.8% Hetastarch	10	10	10	20	10	10	10	20
	0	10	20	20	0	10	20	20
	0	10	20	10	0	10	10	10+
	0	10	20	20	0	10	20	20
	20	0	20	20	20	0	20	20
Mean	6	8	18	18	6	8	16	18
8.1% Hetastarch	20	0	10	10	20	0	20	10
	10	0	20	20	10	0	20	20
	20	0	10	20	20	0	10	20
	30	0	20	20	30	0	20	20
	0	0	20	0	0	0	20	0
Mean	16	0	16	14	16	0	18	14
5.4% Hetastarch	20	10	20	10	20	10	20	10
	10	0	30	0	10	0	10	0
	20	10	10	20	20	10	10	20
	0	10	20	10	0	10	10	10
	10	30	10	0	10	30	10	0
Mean	12	12	18	8	12	12	12	8
+ Organ with Incision								

TABLE 19

Treatment	Overall Adhesion Score
Surgical Control	2.5+
	1.5+
	3+
	3+
	3+
	3+
13.5% Hetastarch	2.5+
	1.5+
	1+
	2+
	2+
	1.5+
16.2% Hetastarch	2+
	2+
	1+
	1+
	1.5+
	1.5+
18.6% Hetastarch	1.5+
	1.5+
	1.5+
	1.5+
	1+
	2+
28.5% Hetastarch	1.5+
	1.5+
	1+
	2+
	1.5+
	1.5+
34.3% Hetastarch	0.5+
	2+
	2+
	2+
	2+
	1+
40% Hetastarch	1+
	1.5+
	2+
	1.5+
	2.5+
	2+
	2+

TABLE 19a

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	40	40	30	30	40	40	30	30+
	0	20	20	30	0	20	20	30
	30	40	30	20	30	40	30	20
	20	30	30	30	20	30	40	30
	40	20	30	30	40	20	30	30+
	30	40	30	30	30	40	30	30+
	40	20	30	30	40	20	30	30
Mean	28.6	30	28.6	28.6	28.6	30	28.6	28.6
13.5% Hetastarch	0	30	20	10	0	30	20	10+
	20	0	30	0	20	0	30	0
	30	20	30	10	30	20	30	10
	30	20	30	0	30	20	20	0
	0	10	20	10	0	10	20	10
	10	20	30	20	10	20	10	20
	30	0	30	20	30	0	20	20
Mean	17.1	14.3	27.1	10	17.1	14.3	21.4	10
16.2% Hetastarch	20	10	20	20	20	0	20	20
	30	0	20	20	30	0	20	20
	0	20	20	0	0	10	20	0
	20	0	30	20	20	0	20	20+
	10	20	20	0	10	20	0	0
	10	0	30	10	10	0	20	10
	0	10	30	30	0	10	30	30
Mean	12.9	8.6	24.3	14.3	12.9	8.6	18.6	14.3
18.6% Hetastarch	20	20	0	20	20	20	20	20+
	0	20	30	10	0	20	20	10
	20	0	30	20	20	0	30	20
	0	10	30	20	0	10	20	20+
	10	0	30	20	10	0	30	20
	50	0	40	40	50	0	40	40
	20	0	20	10	20	0	30	10+
Mean	17.1	7.1	25.7	20	17.1	7.1	27.1	20
23.5% Hetastarch	20	0	30	10	20	0	30	10

EP 0 831 856 B1

TABLE 19a (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Mean	30	20	30	30	30	20	20	30
	10	10	20	20	10	10	30	20+
	20	0	20	20	20	0	20	20
	10	10	30	10	10	10	20	10
	0	0	0	10	0	0	30	0
	20	0	30	20	20	0	30	20
	15.7	5.7	24.3	15.7	15.7	5.7	25.7	15.7
Treatment 28.5% Hetastarch	20	0	20	20	20	0	20	20*
	10	20	20	0	10	20	30	0
	0	0	30	30	0	0	30	30*
	20	10	30	20	20	10	20	20
	20	0	20	20	20	0	30	20
	20	0	20	0	20	10	30	0+
	0	0	20	0	0	0	20	0
Mean	12.9	4.3	22.9	12.9	12.9	5.7	25.7	12.9
34.3% Hetastarch	0	20	30	0	0	20	30	0+
	30	20	10	10	30	20	10	10
	40	10	20	0	40	10	10	0
	30	20	20	20	30	20	30	20
	0	0	20	20	0	0	30	20
	10	0	30	0	10	0	30	0
	0	30	30	20	0	30	20	20
Mean	15.7	14.3	22.9	10	15.7	14.3	22.9	10
40% Hetastarch	20	10	30	20	20	10	40	20
	20	20	0	30	20	20	0	30+
	0	30	30	10	0	30	30	10
	40	0	20	40	40	0	30	40
	10	30	30	20	10	30	30	20*
	0	20	30	20	0	20	20	20
	15	18.3	23.3	23.3	15	18.3	25	23.3

+ Organ with Incision

* Material Present on Horns

[0066] Statistical analysis was performed on the overall score of the nonparametric data taken from Tables 18 and 19. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below.

TABLE 18

ANALYSIS		
Treatment	Rank order	p value
Surgical control	27.6 ± 1.71	--
16.2% Hetastarch	22.2 ± 2.69	0.005
13.5% Hetastarch	11.6 ± 4.20	0.000
10.8% Hetastarch	9.5 ± 0.00	0.000
8.1% Hetastarch	10.0 ± 5.88	0.000
5.4% Hetastarch	12.1 ± 7.08	0.001

TABLE 19

ANALYSIS		
Group	Rank order	p value
Control	47.36 ± 11.91	--
13.5% Hetastarch	27.71 ± 12.59	0.011
16.2% Hetastarch	20.21 ± 12.56	0.001
18.6% Hetastarch	25.71 ± 11.81	0.005
23.5% Hetastarch	27.71 ± 12.59	0.001
28.5% Hetastarch	16.86 ± 11.02	0.000
34.3% Hetastarch	25.79 ± 14.71	0.011
40% Hetastarch	33.42 ± 11.30	0.054

Example 12: Evaluation of HES-7-8:10/Lazaroid compositions

[0067] In this Example, 16.2%, 13.5%, 10.8%, 8.1% and 5.4% (w/v) hetastarch (HES-7-8:10) alone or in combination with (10.8% and 8.1% (w/v) HES-7-8:10 with 0.6 mg/ml lazardoid (U-83836E, available from The UpJohn Company, Kalamazoo, MI, USA), were evaluated for adhesion prevention. Lazardoids were found to have a post-surgical anti-adhesion formation effect as disclosed in co-pending U.S. patent application No.08/341,651 (US 5,614,515), filed November 17, 1994. The composition was administered at the end of surgery in a volume of 5 ml and the animals were sacrificed at day 7. The surgical control received no composition. The statistical analysis based on the data from the double uterine horn model (nonparametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 20 and 21. HES-7-8:10 alone and in combination with lazardoid was efficacious at the reduction of adhesions in the rabbit double uterine horn model.

TABLE 20

Hetastarch + Lazaroid (U-83836E)	
Treatment	Overall Score
Surgical Control	3+
	1.5+
	2.5+
	2+
	3+
16.2% (w/v) Hetastarch	1.5+
	2+
	1.5+
	2+
	1.5+

TABLE 20 (continued)

Hetastarch + Lazaroid (U-83836E)	
Treatment	Overall Score
13.5% Hetastarch	1.5+
	2+
	1.5+
	1.5+
	2.5+
10.8% Hetastarch	2+
	1.5+
	2+
	1.5+
	2+
10.8% Hetastarch + lazaroïd	1+
	1.5+
	1+
	1.5+
	1.5+
8.1% Hetastarch	1.5+
	1+
	Died
	1.5+
	2+
8.1% Hetastarch + lazaroïd	0.5+
	1+
	0.5+
	1+
	0.5+
5.4% Hetastarch	Died
	2+
	1.5+
	1.5+
	2+

TABLE 21

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	40	20	30	20	40	20	30	20
	20	0	10	10	20	0	10	10
	40	30	20	30	40	30	20	30+
	20	10	20	20	20	10	20	20+
	30	20	40	20	30	20	40	20

EP 0 831 856 B1

TABLE 21 (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Mean	30	16	24	20	30	16	24	20
16.2% (w/v) Hetastarch	20	10	20	10	20	10	20	10
	30	10	20	0	30	10	10	0
	10	20	20	0	10	20	20	0
	10	10	20	10	10	10	20	10
	10	0	20	10	10	0	10	10
Mean	16	10	20	6	16	10	16	6
13.5% Hetastarch	0	20	20	10	0	20	20	10
	20	20	30	20	20	20	30	20+
	0	20	20	10	0	20	20	10
	10	0	10	20	10	0	20	20
	30	10	20	10	30	10	20	10
Mean	12	14	20	14	12	14	22	14
10.8% Hetastarch	30	0	20	10	30	0	20	10
	20	0	10	10	20	0	20	10
	10	10	20	10	10	10	20	10
	10	10	10	0	10	10	20	0
	30	10	10	10	30	10	20	10
Mean	20	6	14	8	20	6	20	8
10.8% Hetastarch + Iazaroid	0	0	20	20	0	0	20	20
	10	0	20	10	10	0	10	10
	0	10	10	0	0	10	10	0
	0	20	10	0	0	20	20	0
	10	0	10	10	10	0	10	10
Mean	4	6	14	8	4	6	14	8
8.1% Hetastarch	10	10	20	0	10	10	10	0
	0	10	20	0	0	10	20	0
DIED								
	20	0	10	20	20	0	10	20
	20	10	20	30	20	10	20	30+
Mean	12.5	7.5	17.5	12.5	12.5	7.5	15	12.5
8.1% Hetastarch + Iazaroid	0	0	10	0	0	0	10	0
	10	0	20	0	10	0	20	0
	0	0	10	0	0	0	10	0
	10	0	20	0	10	0	10	0
	10	0	10	0	10	0	0	0
Mean	6	0	14	0	6	0	10	0
5.4% Hetastarch	DIED							
	20	10	20	20	20	10	20	20+
	0	10	20	10	0	10	20	10

TABLE 21 (continued)

% Organ Involvement in Uterine Horn Adhesion								
	DIED							
	10	0	20	20	10	0	20	20
	30	0	20	10	30	0	20	10
Mean	15	5	20	15	15	5	20	15
+ Organ with Incision								

[0068] Statistical analysis was performed on the overall score of the nonparametric data taken from Table 20. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below. Comparison of the rank order of 10.8% HES-7-8:10 with 10.8% HES-7-8:10 containing lazardoid gave a p value of 0.011 and comparison of 8.1% HES-7-8:10 with 8.1% HES-7-8:10 containing lazardoid gave a p value of 0.009.

Treatment	Rank order	p value
Surgical control	31.3 ± 7.96	--
16.2% Hetastarch	21.7 ± 6.37	0.068
13.5% Hetastarch	22.9 ± 8.06	0.136
10.8% Hetastarch	24.3 ± 6.37	0.163
10.8% Hetastarch + lazardoid	12.3 ± 5.14	0.000
8.1% Hetastarch	17.1 ± 8.33	0.035
8.1% Hetastarch + lazardoid	3.6 ± 1.96	0.000
5.4% Hetastarch	23.0 ± 6.50	0.109
5.4% Hetastarch + lazardoid	19.2 ± 9.9	0.000

Example 13: Evaluation of HES-7-8:10/betamethasone

[0069] In this Example, 8.1% (w/v) hetastarch (HES-7-8:10) alone or in combination with 0.005, 0.017, 0.05, 0.17, and 0.5 mg/ml betamethasone sodium phosphate were evaluated for adhesion prevention. Betamethasone (0.017 and 0.17 mg/ml) in saline buffer were used as controls. The surgical controls received no composition. The compositions were administered at the end of surgery in a volume of 10 ml and the animals were sacrificed at day 7. The surgical control received no composition. The statistical analysis based on the data from the double uterine horn model (non-parametric data) was performed on the overall score. The data is rank ordered, a rank value given and an analysis of variance on the ranks is performed. The results are summarized in Tables 22 and 23. HES-7-8:10 alone and in combination with betamethasone was efficacious at the reduction of adhesions in the rabbit double uterine horn model.

TABLE 22

Hetastarch + Betamethasone	
Treatment	Overall Score
Surgical Control	2.5+ 2.5+ 3+ 2+ 3+
8.1% (w/v) Hetastarch	3+ 1.5+ 2+ 1.5+ 1.5+
8.1% (w/v) Hetastarch + 0.5 mg/ml Betamethasone	1.5+

TABLE 22 (continued)

Hetastarch + Betamethasone	
Treatment	Overall Score
	1.5+
	1.5+
	1.5+
	1.5+
8.1% Hetastarch + 0.17 mg/ml Betamethasone	2+
	1.5+
	1+
	2+
8.1% Hetastarch + 0.05 mg/ml Betamethasone	1+
	2+
	1.5+
	1+
8.1% Hetastarch + 0.017 mg/ml Betamethasone	1.5+
	2+
	1.5+
	1.5+
8.1% Hetastarch + 0.005 mg/ml Betamethasone	1.5+
	1.5+
	1.5+
	1.5+
	1.5+
0.17 mg/ml Betamethasone	1+
	1+
	2+
	1.5+
	1+
0.017 mg/ml Betamethasone	1+
	1.5+
	1.5+
	2+
	1+

TABLE 23

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Control	40	0	30	20	40	0	30	20+
	30	30	20	30	30	30	30	30

EP 0 831 856 B1

TABLE 23 (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Mean	50	20	20	20	50	20	20	20+
	50	20	30	30	50	20	30	30
	20	50	20	30	20	50	20	30
	38	24	24	26	38	24	26	26
8.1% (w/v) Hetastarch	50	10	30	20	50	10	30	20+
	0	20	20	20	0	20	10	20
	10	10	30	20	10	10	30	20
	0	10	20	10	0	10	10	10
Mean	10	10	10	0	10	10	10	0
	14	12	22	14	14	12	18	14
8.1% Hetastarch + 0.5 mg/ml betamethasone	10	0	20	10	10	0	10	10
	0	0	20	30	0	0	20	30
	10	0	10	10	10	0	20	10
	20	0	20	0	20	0	30	0
Mean	0	20	10	20	0	20	10	20
	8	4	18	14	8	4	18	14
8.1% Hetastarch + 0.17 mg/ml betamethasone	10	10	10	10	10	10	10	10
	10	0	20	10	10	0	10	10
	0	0	20	20	0	0	20	20
	20	10	10	10	20	10	10	10
Mean	0	10	20	0	0	10	20	0*
	8	6	16	10	8	6	14	10
8.1% Hetastarch + 0.05 mg/ml betamethasone	20	0	20	20	20	0	20	20
	0	10	20	20	0	10	20	20
	10	0	10	0	10	0	10	0
	0	0	20	30	0	0	30	30
Mean	30	0	10	10	30	0	10	10
	12	2	16	16	12	2	18	16
8.1% Hetastarch + 0.017 mg/ml betamethasone	0	10	20	10	0	10	20	10
	10	10	20	20	10	10	20	20
	0	0	30	20	0	0	30	20
	0	0	30	20	0	0	30	20

+ Organ with Incision

* Material Present

TABLE 23 (continued)

% Organ Involvement in Uterine Horn Adhesion								
Treatment	Right Horn				Left Horn			
	Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right
Mean	0	0	20	10	0	0	20	10
	0	20	10	10	0	20	20	10
	2	8	20	14	2	8	22	14
8.1% Hetastarch + 0.005 mg/ml betamethasone	0	20	10	10	0	20	10	10
	0	0	20	20	0	0	20	20
	0	10	20	20	0	10	20	20
Mean	10	0	20	10	10	0	20	10
	10	0	10	10	10	0	20	10
	4	6	16	14	4	6	18	14
0.17 mg/ml betamethasone	0	0	20	10	0	0	20	10
	0	0	20	10	0	0	10	10
	20	0	30	10	20	0	20	10
Mean	0	10	10	10	0	10	10	10
	0	10	10	0	0	10	10	0
	4	4	18	8	4	4	14	8
0.017 mg/ml betamethasone	0	0	20	10	0	0	20	10
	0	0	20	20	0	0	20	20
	0	0	20	20	0	0	10	20
Mean	20	20	10	20	20	20	20	20
	0	0	20	10	0	0	10	10
	4	4	18	16	4	4	16	16

[0070] Statistical analysis was performed on the overall score of the nonparametric data taken from Table 22. The data was rank ordered and assigned a rank value. Analysis of the variance of the ranks was then performed and the resulting student t test results are summarized below.

Treatment	Rank order	p value
Surgical control	41.5 ± 2.74	--
8.1% (w/v) Hetastarch	28.4 ± 9.96	0.022
8.1% Hetastarch + 0.5	20.5 ± 0.00	0.000
8.1% Hetastarch + 0.17	20.5 ± 14.31	0.012
8.1% Hetastarch + 0.05	20.5 ± 10.12	0.002
8.1% Hetastarch + 0.017	23.7 ± 6.40	0.000
8.1% Hetastarch + 0.005	20.5 ± 0.00	0.000
0.17 mg/ml Betamethasone	14.1 ± 12.8	0.002
0.017 mg/ml Betamethasone	17.3 ± 11.97	0.002

Claims

1. Use of a hydroxyethyl starch in the preparation of a medicament for a method for reducing or preventing formation

of post-surgical adhesions between tissue surfaces in a body cavity, said method comprising administering an effective amount of said medicament for a period of time sufficient to permit tissue repair.

2. A use according to claim 1, wherein said tissue repair comprises re-epithelization.
3. A use according to claim 1, wherein said tissue repair comprises mesothelial repair.
4. A use according to claim 1, wherein said hydroxyethyl starch comprises an amylopectin having hydroxyethyl groups which are substituted on a molar ratio ranging between 0.1 and 0.8 of a hydroxyethyl group per glucopyranose unit.
5. A use according to claim 4, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between 3×10^4 and 4×10^6 daltons.
6. A use according to claim 5, wherein said monomers range between 2×10^5 and 2.4×10^6 daltons.
7. A use according to claim 1, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10 or HES-5:10.
8. A use according to claim 1, wherein said medicament includes a physiologically acceptable vehicle.
9. A use according to claim 8, wherein said vehicle comprises sterile water, saline or aqueous buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and tromethamine (TRIS).
10. A use according to claim 8, wherein said vehicle comprises saline, phosphate buffered saline, citrate buffer, and Ringers lactate solution.
11. A use according to claim 1, wherein said medicament further comprises an effective amount of at least one pharmaceutically active agent.
12. A use according to claim 11, wherein said pharmaceutically active agent comprises an anti-adhesion formation agent, an antibiotic agent, an antihistaminic, an anti-inflammatory agent, antifungal agent, amoebocidal agent, trichomonacidal agent, antiprotozoal agent, an antiviral agent, antineoplastic agent or anti-inflammatory corticosteroid.
13. A use according to claim 12, wherein said anti-adhesion formation agent comprises a lazaroid, a retinoid, quina-crine, manoalide, a 5-lipoxygenase inhibitor, ketotifen, dipyridamole a NSAID, or an anti-inflammatory corticosteroid.
14. A use according to claim 12, wherein said anti-inflammatory corticosteroid comprises betamethasone or dexamethasone.
15. Use of hydroxyethyl starch for preparing a medicament for reducing or preventing post-surgical adhesion formation comprising a pharmaceutically active agent and an effective anti-post surgical adhesion amount of hydroxyethyl starch and a pharmaceutical carrier therefor.
16. A use according to claim 15, wherein said hydroxyethyl starch comprises an amylopectin having hydroxyethyl groups which are substituted on a molar ratio ranging between 0.1 and 0.8 of a hydroxyethyl group per glucopyranose unit.
17. A use according to claim 16, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between 3×10^4 and 4×10^6 daltons.
18. A use according to claim 17, wherein said monomers range between 2×10^5 and 2.4×10^6 daltons.
19. A use according to claim 15, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10, or HES-5:10.
20. A use according to claim 19, wherein said hydroxyethyl starch is present in an amount ranging between 0.1% and 60% (w/v).

21. A use according to claim 20, wherein said hydroxyethyl starch is present in an amount ranging between 5.4% and 34.3% (w/v).
22. A use according to claim 15, wherein said pharmaceutically active agent comprises an anti-adhesion formation agent.
23. A use according to claim 15, wherein said anti-adhesion formation agent comprises a lazaroïd, a rétinoïd, quina-crïne, manoalide, a 5-lipoxygénase inhibitor, ketotifen, dipyridamole, a NSAID, or an anti-inflammatoire cortico-steroid.
24. A use according to claim 23, wherein said anti-inflammatoire corticostéroïd comprises betaméthasone or dexaméthasone.
25. A use according to claim 24, wherein said anti-inflammatoire corticostéroïd is présent in an amount ranging between 0.00001 mg/ml and 50 mg/ml.
26. A use according to claim 25, wherein said anti-inflammatoire corticostéroïd is présent in an amount ranging between 0.001 mg/ml and 5 mg/ml.
27. Use of hydroxyethyl starch for preparing a médicament for reducing or preventing formation of post-surgical ad-hésions comprising an anti-adhesion effective amount of hydroxyethyl starch and a pharmaceutical carrier therefor.
28. A use according to claim 27, wherein said hydroxyethyl starch comprises an amylopectin having hydroxyethyl groups which are substituted on a molar ratio ranging between 0.1 and 0.8 of a hydroxyethyl group per glucop-yranose unit.
29. A use according to claim 28, wherein said hydroxyethyl starch comprises amylopectin monomers of molecular weights ranging between 3×10^4 and 4×10^6 daltons.
30. A use according to claim 29, wherein said monomers range between 2×10^5 and 2.4×10^6 daltons.
31. A use according to claim 27, wherein said hydroxyethyl starch comprises HES-1:10, HES-7-8:10 or HES-5:10.
32. A use according to claim 27, wherein said composition includes a physiologically acceptable vehicle.
33. A use according to claim 32, wherein said vehicle comprises sterile water, saline or aqueous buffer solutions containing alkali or alkaline earth metal carbonates, phosphates, bicarbonates, citrates, borates, acetates, succi-nates and trométhamine (TRIS).
34. A use according to claim 32, wherein said vehicle comprises saline, phosphate buffered saline, citrate buffer, and Ringers lactate solution.
35. A use according to claim 27, wherein said composition further comprises an effective amount of at least one phar-maceutically active agent.
36. A use according to claim 35, wherein said pharmaceutically active agent comprises an anti-adhesion formation agent, an antibiotique agent, an antihistaminique, an anti-inflammatoire agent, antifongal agent, amœbocidal agent, trichomonacidal agent, antiprotozoal agent, an antiviral agent, antineoplastique agent or anti-inflammatoire cortico-steroid.
37. A use according to claim 36, wherein said anti-adhesion formation agent comprises a lazaroïd, a rétinoïd, quina-crïne, manoalide, a 5-lipoxygénase inhibitor, ketotifen, dipyridamole, a NSAID, or an anti-inflammatoire cortico-steroid.
38. A use according to claim 36, wherein said anti-inflammatoire corticostéroïd comprises betaméthasone or dexaméthasone.

Patentansprüche

1. Verwendung einer Hydroxyethylstärke bei der Herstellung eines Arzneimittels für ein Verfahren zur Verringerung oder Verhinderung der Bildung von postoperativen Adhäsionen zwischen Gewebeoberflächen in einer Körperhöhle, wobei das Verfahren das Verabreichen einer wirksamen Menge des Arzneimittels während eines ausreichenden Zeitraums, um Gewebereparatur zu ermöglichen, umfaßt.
2. Verwendung nach Anspruch 1, wobei die Gewebereparatur Reepithelisierung umfaßt.
3. Verwendung nach Anspruch 1, wobei die Gewebereparatur Mesothelreparatur umfaßt.
4. Verwendung nach Anspruch 1, wobei die Hydroxyethylstärke ein Amylopectin mit Hydroxyethylgruppen umfaßt, die in einem Molverhältnis im Bereich zwischen 0,1 und 0,8 Hydroxyethylgruppen pro Glucopyranoseeinheit vorhanden sind.
5. Verwendung nach Anspruch 4, wobei die Hydroxyethylstärke Amylopectinmonomere mit Molekulargewichten im Bereich zwischen 3×10^4 und 4×10^6 Dalton umfaßt.
6. Verwendung nach Anspruch 5, wobei die Monomere im Bereich zwischen 2×10^5 und $2,4 \times 10^6$ Dalton liegen.
7. Verwendung nach Anspruch 1, wobei die Hydroxyethylstärke HES-1:10, HES-7-8:10 oder HES-5:10 umfaßt.
8. Verwendung nach Anspruch 1, wobei das Arzneimittel ein physiologisch akzeptables Vehikel umfaßt.
9. Verwendung nach Anspruch 8, wobei das Vehikel steriles Wasser, Salzlösung oder wässrige Pufferlösungen, enthaltend Alkali- oder Erdalkalimetallcarbonate, -phosphate, -bicarbonate, -citrate, -borate, -acetate, -succinate und Trometamol (TRIS), umfaßt.
10. Verwendung nach Anspruch 8, wobei das Vehikel Salzlösung, phosphatgepufferte Salzlösung, Citratpuffer und Ringer-Lactatlösung umfaßt.
11. Verwendung nach Anspruch 1, wobei das Arzneimittel weiterhin eine wirksame Menge mindestens eines pharmazeutischen Wirkstoffs umfaßt.
12. Verwendung nach Anspruch 11, wobei der pharmazeutische Wirkstoff ein Mittel gegen Adhäsionsbildung, ein Antibiotikum, ein Antihistaminikum, ein entzündungshemmendes Mittel, ein fungizides Mittel, ein amöbizides Mittel, ein Mittel gegen Trichomonaden, ein Mittel gegen Protozoen, ein antivirales Mittel, ein antineoplastisches Mittel oder ein entzündungshemmendes Corticosteroid umfaßt.
13. Verwendung nach Anspruch 12, wobei das Mittel gegen Adhäsionsbildung ein Lazaroid, ein Retinoid, Chinacrin, Manoalid, einen 5-Lipoxygenaseinhibitor, Ketotifen, Dipyridamol, ein NSAID oder ein entzündungshemmendes Corticosteroid umfaßt.
14. Verwendung nach Anspruch 12, wobei das entzündungshemmende Corticosteroid Betamethason oder Dexamethason umfaßt.
15. Verwendung von Hydroxyethylstärke zur Herstellung eines Arzneimittels zur Verringerung oder Verhinderung der Bildung von postoperativer Adhäsion, umfassend einen pharmazeutischen Wirkstoff und eine gegen postoperative Adhäsion wirksame Menge von Hydroxyethylstärke, und einen pharmazeutischen Träger dafür.
16. Verwendung nach Anspruch 15, wobei die Hydroxyethylstärke ein Amylopectin mit Hydroxyethylgruppen umfaßt, die in einem Molverhältnis im Bereich zwischen 0,1 und 0,8 Hydroxyethylgruppen pro Glucopyranoseeinheit vorhanden sind.
17. Verwendung nach Anspruch 16, wobei die Hydroxyethylstärke Amylopectinmonomere mit Molekulargewichten im Bereich zwischen 3×10^4 und 4×10^6 Dalton umfaßt.
18. Verwendung nach Anspruch 17, wobei die Monomere im Bereich zwischen 2×10^5 und $2,4 \times 10^6$ Dalton liegen.

19. Verwendung nach Anspruch 15, wobei die Hydroxyethylstärke HES-1:10, HES-7-8:10 oder HES-5:10 umfaßt.
20. Verwendung nach Anspruch 19, wobei die Hydroxyethylstärke in einer Menge im Bereich zwischen 0,1% und 60% (w/v) vorhanden ist.
- 5 21. Verwendung nach Anspruch 20, wobei die Hydroxyethylstärke in einer Menge im Bereich zwischen 5,4% und 34,3% (w/v) vorhanden ist.
22. Verwendung nach Anspruch 15, wobei der pharmazeutische Wirkstoff ein Mittel gegen Adhäsionsbildung umfaßt.
- 10 23. Verwendung nach Anspruch 15, wobei das Mittel gegen Adhäsionsbildung ein Lazaroid, ein Retinoid, Chinacrin, Manoalid, einen 5-Lipoxygenaseinhibitor, Ketotifen, Dipyridamol, ein NSAID oder ein entzündungshemmendes Corticosteroid umfaßt.
- 15 24. Verwendung nach Anspruch 23, wobei das entzündungshemmende Corticosteroid Betamethason oder Dexamethason umfaßt.
- 25 25. Verwendung nach Anspruch 24, wobei das entzündungshemmende Corticosteroid in einer Menge im Bereich zwischen 0,00001 mg/ml und 50 mg/ml vorhanden ist.
- 20 26. Verwendung nach Anspruch 25, wobei das entzündungshemmende Corticosteroid in einer Menge im Bereich zwischen 0,001 mg/ml und 5 mg/ml vorhanden ist.
- 25 27. Verwendung von Hydroxyethylstärke zur Herstellung eines Arzneimittels zur Verringerung oder Verhinderung der Bildung von postoperativen Adhäsionen, umfassend eine gegen Adhäsion wirksame Menge von Hydroxyethylstärke, und einen pharmazeutischen Träger dafür.
- 30 28. Verwendung nach Anspruch 27, wobei die Hydroxyethylstärke ein Amylopectin mit Hydroxyethylgruppen umfaßt, die in einem Molverhältnis im Bereich zwischen 0,1 und 0,8 Hydroxyethylgruppen pro Glucopyranoseeinheit vorhanden sind.
- 35 29. Verwendung nach Anspruch 28, wobei die Hydroxyethylstärke Amylopectinmonomere mit Molekulargewichten im Bereich zwischen 3×10^4 und 4×10^6 Dalton umfaßt.
- 30 30. Verwendung nach Anspruch 29, wobei die Monomere im Bereich zwischen 2×10^5 und $2,4 \times 10^6$ Dalton liegen.
31. Verwendung nach Anspruch 27, wobei die Hydroxyethylstärke HES-1:10, HES-7-8:10 oder HES-5:10 umfaßt.
- 40 32. Verwendung nach Anspruch 27, wobei die Zusammensetzung ein physiologisch akzeptables Vehikel umfaßt.
33. Verwendung nach Anspruch 32, wobei das Vehikel steriles Wasser, Salzlösung oder wässrige Pufferlösungen, enthaltend Alkali- oder Erdalkalimetallcarbonate, -phosphate, -bicarbonate, -citrate, -borate, -acetate, -succinate und Trometamol (TRIS), umfaßt.
- 45 34. Verwendung nach Anspruch 32, wobei das Vehikel Salzlösung, phosphatgepufferte Salzlösung, Citratpuffer und Ringer-Lactatlösung umfaßt.
- 50 35. Verwendung nach Anspruch 27, wobei das Arzneimittel weiterhin ein wirksame Menge mindestens eines pharmazeutischen Wirkstoffs umfaßt.
- 55 36. Verwendung nach Anspruch 35, wobei der pharmazeutische Wirkstoff ein Mittel gegen Adhäsionsbildung, ein Antibiotikum, ein Antihistaminikum, ein entzündungshemmendes Mittel, ein fungizides Mittel, ein amöbizides Mittel, ein Mittel gegen Trichomonaden, ein Mittel gegen Protozoen, ein antivirales Mittel, ein antineoplastisches Mittel oder ein entzündungshemmendes Corticosteroid umfaßt.
37. Verwendung nach Anspruch 36, wobei das Mittel gegen Adhäsionsbildung ein Lazaroid, ein Retinoid, Chinacrin, Manoalid, einen 5-Lipoxygenaseinhibitor, Ketotifen, Dipyridamol, ein NSAID oder ein entzündungshemmendes Corticosteroid umfaßt.

38. Verwendung nach Anspruch 36, wobei das entzündungshemmende Corticosteroid Betamethason oder Dexamethason umfaßt.

Revendications

1. Utilisation d'hydroxyéthyle amidon dans la préparation d'un médicament destiné à un procédé pour réduire ou prévenir la formation d'adhérences post-chirurgicales entre les surfaces tissulaires dans la cavité d'un corps, ladite méthode comprenant l'administration d'une quantité efficace dudit médicament pendant une période de temps suffisante pour permettre la réparation du tissu.
2. Utilisation selon la revendication 1, dans laquelle ladite réparation de tissu est constituée d'une réépithélialisation.
3. Utilisation selon la revendication 1, dans laquelle ladite réparation tissulaire est constituée d'une réparation mésothéliale.
4. Utilisation selon la revendication 1, dans laquelle ledit hydroxyéthyle amidon est composé d'une amylopectine possédant des groupes hydroxyéthyles qui sont substitués selon un rapport molaire dans la gamme de 0,1 et 0,8 d'un groupe hydroxyéthyle par unité de glucopyranose.
5. Utilisation selon la revendication 4, dans laquelle ledit hydroxyéthyle amidon est composé de monomères d'amylopectine de poids moléculaire dans la gamme entre 3×10^4 et 4×10^6 daltons.
6. Utilisation selon la revendication 5, dans laquelle lesdits monomères sont dans la gamme de 2×10^5 et $2,4 \times 10^6$ daltons.
7. Utilisation selon la revendication 1, dans laquelle ledit hydroxyéthyle amidon est composé de HEA (hydroxyéthyle amidon)-1 :10, HEA-7-8 :10 ou HEA-5 :10.
8. Utilisation selon la revendication 1, dans laquelle ledit médicament comprend un support physiologiquement acceptable.
9. Utilisation selon la revendication 8, dans laquelle ledit support est composé d'eau stérile, de solutions tampon aqueuses ou salines contenant des carbonates de métaux alcalins ou alcalino-terreux, des phosphates, des bicarbonates, des citrates, des borates, des acétates, des succinates de métaux alcalins ou alcalino-terreux et de la trométhamine (TRIS).
10. Utilisation selon la revendication 8, dans laquelle ledit support est composé d'une solution saline, d'une solution saline tamponnée au phosphate, d'un tampon citrate, et d'une solution lactate de Ringer.
11. Utilisation selon la revendication 1, dans laquelle ledit médicament est composé en plus d'une quantité efficace d'au moins un agent pharmaceutiquement actif.
12. Utilisation selon la revendication 11, dans laquelle ledit agent pharmaceutiquement actif est composé d'un agent d'anti formation d'adhérences, d'un agent antibiotique, d'un antihistaminique, d'un agent anti-inflammatoire, d'un agent anti-fongique, d'un agent amibocide, d'un agent anti-trichomonas, d'un agent anti- protozoaire, d'un agent antiviral, d'un agent antinéoplasique ou d'un corticostéroïde anti-inflammatoire.
13. Utilisation selon la revendication 12, dans laquelle ledit agent anti-formation d'adhérence est composé d'un lazaroïde, d'un rétinoïde, de mépacrine, d'un manoalide, d'un inhibiteur de la 5-lipoxygénase, de kétotifène, de dipyridamole, d'un NSAID (médicament anti-inflammatoire non stéroïdien) ou d'un corticostéroïde anti-inflammatoire.
14. Utilisation selon la revendication 12, dans laquelle ledit corticostéroïde anti-inflammatoire est composé de bétaméthasone ou de dexaméthasone.
15. Utilisation d'hydroxyéthyle amidon pour la préparation d'un médicament pour réduire ou prévenir la formation d'adhérences post-chirurgicales composé d'un agent pharmaceutiquement actif et d'une quantité anti-adhérence post-chirurgicale efficace d'hydroxyéthyle amidon et d'un support pharmaceutique qui en dérive.

16. Utilisation selon la revendication 15, dans laquelle ledit hydroxyéthyle amidon est composé d'une amylopectine possédant des groupes hydroxyéthyles qui sont substitués dans un rapport molaire dans la gamme de 0,1 à 0,8 de groupes hydroxyéthyles par unité de glucopyranose.
- 5 17. Utilisation selon la revendication 16, dans laquelle ledit hydroxyéthyle amidon est composé de monomères d'amylopectine de poids moléculaires dans la gamme de 3×10^4 à 4×10^6 daltons.
18. Utilisation selon la revendication 17, dans laquelle lesdits monomères sont dans une gamme de 2×10^5 à $2,4 \times 10^6$ daltons.
- 10 19. Utilisation selon la revendication 15, dans laquelle ledit hydroxyéthyle amidon est composé de HEA-1 :10, HEA-7-8 :10, ou HEA-5 :10.
- 15 20. Utilisation selon la revendication 19, dans laquelle ledit hydroxyéthyle amidon est présent dans une quantité dans la gamme de 0,1% à 60%(p/v).
21. Utilisation selon la revendication 20, dans laquelle ledit hydroxyéthyle amidon est présent dans une quantité dans la gamme de 5,4% à 34,3%(p/v).
- 20 22. Utilisation selon la revendication 15, dans laquelle ledit agent pharmaceutiquement actif est composé d'un agent anti formation d'adhérence.
23. Utilisation selon la revendication 15, dans laquelle ledit agent anti-formation d'adhérence est composé d'un lazaroïde, d'un rétinoïde, de mépacrine, d'un manoalide, d'un inhibiteur de la 5-lipoxygénase, de kétotifène, de dipyridamole, de NSAID, ou d'un corticostéroïde anti-inflammatoire.
- 25 24. Utilisation selon la revendication 23, dans laquelle ledit corticostéroïde anti-inflammatoire est composé de bétaméthasone ou de dexaméthasone.
- 30 25. Utilisation selon la revendication 24, dans laquelle ledit corticostéroïde anti-inflammatoire est présent dans une gamme de quantités de 0,00001 mg/ml à 50 mg/ml.
26. Utilisation selon la revendication 25, dans laquelle ledit corticostéroïde anti-inflammatoire est présent dans une gamme de quantités de 0,001 mg/ml à 5 mg/ml.
- 35 27. Utilisation de l'hydroxyéthyle amidon pour la préparation d'un médicament pour réduire ou prévenir la formation d'adhérences post-chirurgicales composé d'une quantité anti-adhérence efficace d'hydroxyéthyle amidon et d'un support pharmaceutique qui en dérive.
- 40 28. Utilisation selon la revendication 27, dans laquelle ledit hydroxyéthyle amidon est composé d'amylopectine possédant des groupes hydroxyéthyles qui sont substitués dans un rapport molaire dans la gamme de 0,1 à 0,8 de groupes hydroxyéthyles par unité de glucopyranose.
- 45 29. Utilisation selon la revendication 28, dans laquelle ledit hydroxyéthyle amidon est composé de monomères d'amylopectine de poids moléculaires dans la gamme de 3×10^4 à 4×10^6 daltons.
30. Utilisation selon la revendication 29, dans laquelle lesdits monomères sont dans la gamme de 2×10^5 à $2,4 \times 10^6$ daltons.
- 50 31. Utilisation selon la revendication 27, dans laquelle ledit hydroxyéthyle amidon est composé de HEA-1 :10, HEA-7-8 :10 ou HEA-5 :10.
32. Utilisation selon la revendication 27, dans laquelle ladite composition comprend un véhicule physiologiquement acceptable.
- 55 33. Utilisation selon la revendication 32, dans laquelle ledit véhicule est composé d'eau stérile, de solutions tampon aqueuses ou salines contenant des carbonates, des phosphates, des bicarbonates, des citrates, des borates, des acétates des succinates de métaux alcalins ou alcalino-terreux et de la trométhamine (TRIS).

34. Utilisation selon la revendication 32, dans laquelle ledit véhicule est composé d'une solution saline, d'une solution saline tamponnée au phosphate, d'un tampon citrate, et d'une solution lactate de Ringer.

5 35. Utilisation selon la revendication 27, dans laquelle ladite composition est de plus composée d'une quantité efficace d'au moins un agent pharmaceutiquement actif.

10 36. Utilisation selon la revendication 35, dans laquelle ledit agent pharmaceutiquement actif est composé d'un agent anti formation d'adhérence, d'un agent antibiotique, d'un antihistaminique, d'un agent anti-inflammatoire, d'un agent antifongique, d'un agent amibocide, d'un agent anti trichomonas, d'un agent anti protozoaires, d'un agent antiviral, d'un agent anti-néoplasique ou d'un corticostéroïde anti-inflammatoire.

15 37. Utilisation selon la revendication 36, dans laquelle l'agent anti formation d'adhérence est composé d'un lazaroïde, d'un rétinoïde, de mépacrine, d'un manoalide, d'un inhibiteur de la 5-lipoxycgénase, de kétotifène, de dipyridamole, d'un NSAID, ou d'un corticostéroïde anti-inflammatoire.

20 38. Utilisation selon la revendication 36, dans laquelle ledit corticostéroïde anti-inflammatoire est composé de bêta-méthasone ou de dexaméthasone.

25

30

35

40

45

50

55